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ATTIVITÀ DI RICERCA 
Durante il Dottorato di ricerca mi sono occupato dello studio della regolazione 
dell´espressione genica in Neisseria meningitidis. In particolare ho studiato la regolazione 
trascrizionale mediata dal repressore NadR, in risposta a segnali presenti nell’ospite e di 
rilevanza fisiologica. Ho caratterizzato il meccanismo molecolare di repressione mediato 
da NadR sui suoi geni target e il meccanismo mediante il quale molecole presenti nei siti 
d’infezione del meningococco alterano l’attività regolatoria di NadR. Infine, ho studiato 
l’impatto della regolazione mediata da NadR su l’antigene NadA, sulla copertura di un 
nuovo vaccino meningococcico, chiamato 4CMenB.  
In parallelo, ho indagato il ruolo nella regolazione trascrizionale di piccoli RNA non 
codificanti indotti in diverse condizioni e/o stress incontrati dal meningococco durante la 
sua patogenesi.      
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1 INTRODUCTION 
1.1 Meningococcal disease 
Neisseria meningitidis, otherwise known as meningococcus, is an exclusively human 
pathogen, which represents a major cause of meningitis and sepsis, devastating 
meningococcal disease, which can kill children and young adults within hours despite the 
availability of effective antibiotics. 
Meningococcal disease was first reported in 1887 by Anton Weichselbaum, who 
described the meningococcal infection of the cerebrospinal fluid of a patient [1]. Each 
year there are an estimated 1.2 million cases of invasive meningococcal disease and 
135,000 deaths. During epidemics the incidence of meningococcal disease can rise above 
1 per 1,000 persons [2, 3]. Despite availability of antibiotic treatment, approximately 10 
to 14% of people who contract meningococcal disease die, with a rate between 40-55% 
among patients with meningococcal sepsis [4, 5]. Approximately 11 to 19% of individuals 
surviving the disease often suffer from permanent sequelae, including neuro-
developmental deficits, hearing loss, seizures, ataxia, hemiplegia as well as amputation of 
limbs [4, 6-8]. 
Most cases of meningococcal disease occur in otherwise healthy individuals without 
identified risk factors and for reasons not fully understood. However, certain biological, 
environmental and social factors have been associated with an increased risk of disease. 
Infants under 1 year of age, with a peak between 0 and 7 months, are the population at 
highest risk of infection due to their immature immune systems (6.33-7.08 cases per 
100,000). A second peak in incidence is observed in adolescents and young adults (14-24 
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years; 0.75 cases per 100,000) largely due to increased carriage in this population [9]. 
Microbial factors influencing its virulence, environmental condition facilitating exposure 
and acquisition, impaired immune system, genetic polymorphisms and naso- and 
oropharyngeal irritation caused by smoking and respiratory tract infection, represent 
important factors for disease development [4, 10-15]. 
As the classic signs and symptoms, such as rash, fever, and headache, are unspecific 
mainly in the early course, diagnosis of meningococcal disease becomes challenging and 
may be mis-diagnosed. Due to the rapid progression of meningococcal disease, if 
appropriate treatment is delayed and sometimes despite early antibiotic treatment, it can 
lead to death within 24 to 48 hours from the first sign of symptoms [6]. 
Meningococcal disease occurs mainly as sporadic cases in industrialized countries, even if 
small regions suffer from epidemic outbreaks (e.g. New Zealand). On the contrary, it is 
largely epidemic in the so-called “meningitidis belt” in the sub-Saharan Africa.  
 
1.2 The pathogen 
Neisseria meningitidis is a β-proteobacterium, gram-negative, bean-shaped diplococcus 
(Figure 1.1) and member of the bacterial family of Neissiriaceae. As a Gram negative, it 
has an outer membrane composed of lipids, outer membrane proteins (OMPs), and 
lipooligosaccharide (LOS), the peptidoglycan layer and the inner membrane. A 
polysaccharide capsule is ususllay attached to the outer membrane of meningococcus. 
Pathogenic strains are almost always encapsulated, however the invasive potential of non 
encapsulated disease isolates has recently been reported [16]. It is aerobic and requires 
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glucose, pyruvate or lactate as carbon sources [17], optimal growth occurs at 35-37 °C 
with 5-10% (v/v) CO2. It is non-motile and non-sporulating and generally piliated.  
 
 
Figure 1.1 - Neisseria meningitidis diplococci. 
(A) Meningococcal diplococci indicated by the black arrow in proximity and within leukocytes in the 
cerebrospinal fluid (Gram staining, modified from [18]). (B) Colored scanning electron micrograph (SEM) of 
Neisseria meningitidis bacteria on human epithelium (modified from www.sciencephoto.com). 
 
1.2.1 Classification and epidemiology 
Meningococci strains are traditionally classified by serologic typing systems depending on 
the structural differences and therefore the immunological reactivity of surface exposed 
epitopes on the outer membrane or the capsule. 10 serosubtypes and 20 serotypes have 
been defined according to antigenic properties of outer membrane PorA and PorB 
proteins, respectively [19] as well as 13 immunotypes depending on LOS differences [20, 
21]. On the basis of the bacterial polysaccharide capsule, at least 12 different serogroups 
have been identified (A, B, C, E-29, H, I, K, L, W  , X, Y, Z). Out of these, six are responsible 
for more than 90% of meningococcal disease worldwide: A, B, C, X, Y and W [2, 22-24].  
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These serogroups are distributed widely and differently from one part of the globe to the 
other. In Europe, South America and Australia, serogroups B and C predominate, whereas 
in Asia serogroups A and C are the most common. In North America, most meningococcal 
disease is caused by serogroups B, C, and Y [25, 26]. In Africa, epidemics occur every 8-10 
years and serogroup A, historically the serogroup responsible for the larger epidemics, is 
responsible for most cases in the “meningitis belt" region, even if serogroup W also 
causes a substantial proportion of cases [2, 27, 28], (Figure 1.2). 
Meningococcal immuno-evasion phenomena such as high frequency phase and antigenic 
variation of outer-membrane structures as well as horizontal gene transfer enhance the 
virulence of meningococci by conferring them genotypic and phenotypic diverstiy and 
there is also evidence of capsular switching [29-31]. For this reason serotyping is not 
suitable for modern epidemiology. DNA-based approaches have been developed to 
characterize meningococcal strains including pulsed-field gel electrophoresis (PFGE), multi 
locus enzyme electrophoresis (MLEE) and PCR [32-35]. A genetic typing system based on 
polymorphisms in multiple housekeeping genes, called Multi Locus Sequence Typing 
(MLST), is now the gold standard for molecular typing and epidemiologic studies. MLST 
characterizes isolates on the basis of the nucleotide sequences of internal fragments of 
seven housekeeping genes defining their sequence type (ST) [36]. Menigococci can in this 
way be classified into lineages, termed clonal complexes (CC). A clonal complex is a group 
of STs that share at least four of the seven loci in common with a central ancestral 
genotype [37]. Despite huge diversity in meningococcal population, only a minority of 
these clonal complexes are associated with invasive disease, known as hyper-invasive 
lineages [38]. ST-1, ST-4 and ST-5 complexes are restricted nearly exclusively to serogroup 
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A strains, ST-11 is associated both to C and W-135 serogroups, ST8, ST-32 and ST41/44 
are associated with serogroup B worldwide together with the more recent ST-269, while 
ST-23 complex is associated with serogroup Y[39]. Why hyper-invasive meningococcal 
lineages are more pathogenic than others remains still unknown. 
 
 
Figure 1.2 - Global distribution of invasive meningococcal serogroups. 
The image summarizes the serogroup-specific incidence in different geographical areas of the world 
(modified from www.meningitisinfo.com). 
 
1.2.2 Pathogenesis 
The pathogenesis of Neisseria meningitidis is a complex multi-stage process (Figure 1.3). 
Meningococci may be acquired via respiratory droplets or saliva. The asymptomatic 
meningococcal colonization of the upper respiratory tract is common and is found in 
approximately 10-15% of healthy adults [2]. This carrier state represents a successful 
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commensal relationship between the host and the bacterium: it provides the only known 
reservoir for the human-adapted meningococcal infection and may also contribute to 
establishing host immunity [40]. Meningococcal carriage is very low in the first years of 
life (4.5% in infancy), whereas it is highest in adolescents and young adults, peaking at 10-
35% in 20-24-year olds [41, 42] before decreasing to about 8-10% in older than 50 years 
of age [41, 43]. Compared with the carriage rate, meningococcal disease is rare; however 
in a small subset of cases the colonization represents the initial step of disease.   
 
 
Figure 1.3 - Stages in the pathogenesis of Neisseria meningitidis. 
The image summarizes the steps during meningococcal colonization and infection. Detailed description is 
reported in the text. Modified from [44]. 
 
The initial contact with nasopharyngeal epithelial cells is mediated by Type IV pili, which 
may recognize the host receptor CD46 [45], but this remains controversial. Then, 
meningococci proceed to proliferate on the surface of human non-ciliated epithelial cells, 
forming small micro-colonies at the site of initial attachment [40]. After the initial 
colonization, there is a loss or down regulation of the capsule, which sterically masks the 
outer membrane proteins. This event is thought to occur both via cell contact induced 
1     INTRODUCTION   
 
 
 
15 
 
repression [46], and by selection of low or no-capsule expressing bacteria due to phase 
variation [47]. Close adherence of meningococci to the host epithelial cells is mediated by 
a variety of possible redundant adhesins, previously masked by the capsule, resulting in 
the appearance of cortical plaques [40].  
At this stage of colonization meningococci can invade the pharyngeal mucosal epithelium. 
One trigger of meningococcal internalization is represented by interaction of the bacterial 
opacity proteins, Opa and Opc, with CD66/CEACAMs and integrins, respectively, on the 
surface of the epithelial cell [48]. Meningococci can be internalized through the 
recruitment of factors leading to the formation and extension of epithelial cell 
pseudopodia that engulf the bacteria within intracellular vacuoles [49, 50]. Once 
internalized in the epithelial cells meningococcus can evade the host immune response, 
find more available nutrients and survive thanks to factors including IgA1 protease, which 
degrades lysosome-associated membrane proteins [51]. Meningococci are capable of 
intracellular replication partly due to the capacity of the organism to acquire iron through 
specialized transport systems, such as the hemoglobin binding receptor (HmbR), 
transferring binding protein (TbpAB) and lactoferrin binding protein (LbpAB) [52]. 
In healthy individuals, bacteria that cross the mucosal epithelium are eliminated through 
serum bactericidal activity. However, in susceptible individuals, meningococcus can 
occasionally cross the mucosal epithelial barrier through either transcytosis or directly 
following damage to the monolayer integrity or through phagocytes in a ‘Trojan horse’ 
manner [44] and eventually enter the bloodstream surviving the host defense 
mechanism. Survival in blood is promoted by mechanisms such as up-regulation of 
capsule expression, as it provides resistance to antibiotic- and complement- mediated 
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killing and inhibits phagocytosis [53], and recruitment of both negative regulators of the 
complement cascade, such us factor H recruited by factor H-binding protein (fHbp) [54] 
and NspA [55], and complement regulators, such as C4-binding protein (C4bp), bound by 
PorA porins [56]. Once inside the blood, the meningococci face two fates: either the 
bacteria multiply slowly in the blood, eventually passing across the brain vascular 
endothelium (or the epithelium of the choroid plexus) and seeding local sites, resulting in 
infection of the meninges and the cerebrospinal fluid [57], or they undergo rapid 
multiplication in the bloodstream, resulting in clinical features of bacterial septicemia or 
meningococcemia [4, 58]. 
Meningococcal disease represents a failed or dysfunctional relationship with the host, 
and the factors that trigger menicococcal entrance in the blood are not yet fully 
understood but should be dependent on both the host and pathogen and include 
impairment of the integrity of the human nasopharyngeal mucosa, the lack of a 
protective immune response and microbial factors influencing virulence [2, 3, 59]. 
 
1.3 Genetics 
The genome sequences of many disease strains and carriage strains have been reported, 
showing that the circular meningococcal chromosome is between 2.0 and 2.2 megabases 
in size and contains about 2000 genes [60-62]. The meningococcus shares about 90% 
nucleotide homology with either Neisseria gonorrhoeae or the commensal Neisseria 
lactamica. 70% of the genome encodes for essential metabolic functions. 10% of the 
genome is represented by mobile elements, such as IS elements and prophage sequences 
[60], leading to DNA transfer between meningococci, gonococci, commensal spp. as well 
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as other bacteria (e.g. Haemophilus) [63]. Except for the IHT-A1 capsule locus, no specific 
core pathogenome has been identified [64], suggesting that virulence may be dependent 
on multiple redundant genes, and therefore polygenic in nature. The acquisition of the 
capsule locus by horizontal gene transfer, possibly from Pasteurella multocida or P. 
hemolytica, appears to be a major event in the evolution of the pathogenicity of the 
meningococcus from an un-encapsulated ancestor [40, 61]. 
The GC percentage is widely variable along the chromosome with an average of 51.63%, 
with defined regions of low GC content that likely have been acquired by a relatively 
recent horizontal gene transfer [65]. These events are common in N. meningitidis due to 
its natural transformation competence [66]. Another characteristic of the meningococcal 
genome is the abundance of repetitive DNA sequences, polymorphic regions and genetic 
switches (e.g. slipped-strand mispairing), leading to genetic instability, duplication or 
deletion of regions of the genome, as well as genetic recombination [63, 67]. About 20% 
of the genome consists of repeated regions of different natures [68]. In summary, a 
central characteristic of the genome is its plasticity contributing to the non-clonal 
behaviour of meningococcus and phenotypic diversity, which allow the bacteria to 
successfully adapt and invade the host.  
 
1.4 Gene regulation and adaptation to the host environment 
During infection, N. meningitdis can invade diverse sites within the human host, which 
represent different niches with respect to nutrients, environmental factors and 
competing microorganisms. Therefore it is subjected to constant selective pressures and 
its ability to rapidly adapt its metabolism and cellular composition to environmental 
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changes is essential for its survival [69]. Bacteria have two major and complementary 
mechanisms for adapting to changes in their environment: changing their genotype 
(genome plasticity) or altering gene expression, both leading to phenotypic variations.  
 
1.4.1 Genome plasticity 
The high natural competence of meningococci is a leading cause of horizontal gene 
transfer and therefore genome variability. In addition, the above mentioned abundance 
of repetitive DNA sequences contributes to genome plasticity. The most frequent repeat 
sequence element is the Neisserial DNA uptake sequence (DUS). There are nearly 2000 
copies of this 12-bp sequence, involved in recognition and uptake of DNA from 
environment [70]. The 20 bp long dRS3 elements, comprising 6 bp terminal inverted 
repeats, promote both permanent genomic changes, such as insertion and chromosomal 
rearrangement [61], and recombination with exogenous DNA [71]. Correia elements, 
(CEs), are mobile elements of 100-150 bp, comprising 26 bp inverted repeats, which carry 
transcription initiation sequences as well as binding sites for DNA bending protein, 
suggesting a role in modulating the expression of nearby genes [72, 73]. Finally the 
meningococcal genome is also littered with insertion sequences (IS) [74] and other repeat 
sequences with incompletely determined functions such as, AT-rich repeats [60] and REP2 
repeats [75]. 
Phase variation (PV). PV is the adaptive process by which bacteria undergo frequent and 
reversible phenotypic changes resulting from genetic alterations in specific loci of their 
genomes. Short tandem sequence repeats are the basis for PV, which can occur during 
replication through slipped-strand mispairing (SSM, Figure 1.4), altering the unit number 
1     INTRODUCTION   
 
 
 
19 
 
of these repeats. The presence of repeat units may cause a slippage during replication of 
either the synthesis strand, generating addition events, or the template strand, leading to 
deletions in the new born filament [63]. When repeats occur in the coding sequence, 
close to or in the promoter region, they can change the transcriptional and translational 
state of the gene, by introducing frameshift mutations or changing critical promoter 
spacing.  This results in either an on/off switching or an altered level of the gene 
expression and hence function and antigenicity of the encoded proteins [47, 76-78]. In 
most loci, known or predicted to be controlled by PV, changes in DNA repeat length 
produce reversible translational frameshift mutations in the coding sequence of the gene, 
thereby switching the expression of the encoded protein ‘on’ or ‘off’ [79]. On the other 
hand, the phase variable repeat tracts in the porA, fetA, and opc genes are located 
between the -10 and the -35 promoter elements and are thought to result in altered 
sigma-factor binding [77, 78, 80]. The phase regulation of the Neisserial Adhesin A 
(NadA), is particular, altering the level of expression of nadA and will be discussed below. 
It has been proposed that in N. meningitidis over 100 genes are potentially phase 
variable, altering mainly virulence-associated, surface-exposed molecules such as outer-
membrane proteins PorA, Opc, Opa, pili and specific adhesins, as well as LPS and capsule 
[63, 81, 82]. It has been demonstrated that meningococcal strains associated with disease 
have high frequency of phase variation, indicating a substantial benefit in varying surface 
components during invasion and/or transmission between hosts [83, 84]. 
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Figure 1.4 - Slipped-strand mispairing. 
Slipped-strand nucleotide mispairing can generate variation in gene expression. Illegitimate base pairing in 
regions of repetitive DNA during replication, coupled with inadequate DNA mismatch repair systems, can 
produce deletions or insertions of repeat units. Bulging in the replicated and template strands gives rise to 
larger and smaller numbers of repeat units, respectively. The figure shows a strand of DNA (blue) being 
carried through two rounds of replication. From [85]. 
 
Antigenic variation. Antigenic variation is a mechanism of immune evasion and refers to 
the expression of functionally conserved moieties that are antigenically distinct within a 
clonal population [86]. Only one variant is expressed at any given time, although the cell 
contains the genetic information (or acquires the genetic potential through DNA uptake) 
to produce a whole range of antigenic variants. This process is distinct from phase 
variation, as the antigen is consistently produced, but in different forms. In the 
pathogenic Neisseria species, antigenic variation occurs in several surface components, 
including type IV pili, lipooligosaccharides and opa proteins [63, 87, 88]. 
 
1.4.2 Transcriptional regulators 
Survival under the extreme and rapidly changing conditions of the host requires timely 
and appropriate alterations in gene expression and protein activity, which occur in a 
bacterial cell in response to stimuli signalling these new environmental conditions. At the 
transcriptional level, these alterations could be controlled by global factors, for example 
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through changes in associations between different alternative sigma factors and core RNA 
polymerase, which essentially reprogram promoter recognition specificities of the 
enzyme to allow expression of new sets of target genes [89]. Although extensive 
transcriptional regulation is expected to accompany the infection process of 
N.meningitidis, only 36 putative transcriptional regulators (according to the 
Comprehensive Microbial Resource database, http://cmr.jcvi.org) are encoded by the 
meningococcal genome, compared to Escherichia coli, which harbors more than 200 
transcriptional regulators. This reveals a striking limitation for transcriptional regulation, 
which is possibly related to the restricted ecological niches of the Neisseriacae [90]. Only 
few of the predicted regulators have been characterized and the regulons of even fewer 
have been deeply studied, involed in the adaptation of meningococcus to iron and oxygen 
limitation and response to nitric oxide.  
The Ferric Uptake Regulator (Fur). It has been very well established that bacterial 
pathogenesis and survival are dependent on the ability to acquire iron within the host 
[91, 92]. Cell growth and multiplication, in fact, require essential nutrients such as iron, 
which is limiting in the human host being sequestrated by human iron proteins. Although 
N. meningitidis does not produce siderophores for iron acquisition, it possesses outer 
membrane receptors that have been postulated to scavenge the iron-loaded 
siderophores secreted by other bacteria colonizing the nasopharyngeal tract [93] such as 
the hemoglobin binding receptor (HmbR), transferring binding protein (TbpAB) and 
lactoferrin binding protein (LbpAB) [52]. However, iron overload results in toxicity for the 
bacterium; therefore, iron uptake is tightly regulated, as in many bacteria, by Fur [94, 95]. 
Fur senses internal iron concentration and binds to and represses iron uptake genes using 
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ferrous iron as a co-repressor [96-98]. Fur has been also reported to act positively in the 
expression of certain genes. The regulon of Fur comprises more than 200 gene [99] 
regulated either with a direct mechanism (binding upstream promoter sequences [96]) or 
an indirect mechanism which involves a posttranscriptional regulation mediated by a Fur 
repressed small regulatory RNA named NrrF [100, 101]. 
The Fumarate and Nitrate reductase Regulator protein (FNR). During its infection N. 
meningitidis is exposed to highly divergent partial pressures of oxygen (high in the upper 
respiratory tract and low in the mucus membranes and in the blood [102]. It has been 
shown that although N. meningitides fails to grow under strictly anaerobic conditions, 
under oxygen limitation the bacterium express a denitrification pathway system that 
supplements growth [103, 104]. The transcriptional activator FNR enables the 
meningococci to survive under oxygen limitation by inducing sugar fermentation and 
denitrification pathways, utilizing nitrite and nitric oxide as electron acceptors [105, 106]. 
FNR binds to DNA and activates target genes, involved in bacterial anaerobic metabolism 
as a dimer containing [4Fe-4S] cluster, during oxygen limitation. This cluster dissociates in 
the presence of oxygen, destabilizing the dimer, with loss of FNR activity [106-108]. Only a 
total of 9 transcriptional units have been identified as being part of the regulon of FNR 
[106]. Interestingly factor H binding protein (fHBP) which enables the bacterium to evade 
complement-mediated killing by binding factor H [54, 109], has been shown to be 
positively regulated by oxygen limitation through a FNR dedicated promoter [110]. This 
result, together with the observation that a knock-out of FNR in N.menigitidis is 
attenuated in the mouse and infant rat animal models of infection [106], indicate the 
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importance of these responses for the pathogenesis and the survival of meningococcus in 
the human host.  
The Nitric oxide (NO)-sensitive Repressor (NsrR). N. meningitidis is exposed to the free-
radical gas nitric oxide (NO), generated both internally by its own metabolism and 
externally by the human host tissue in its natural habitat, which is rich in macrophages, a 
potent source of NO during infection [111, 112]. On one hand, meningococcus 
synthesizes NO detoxification proteins that protect the organism from being killed by the 
toxicity of extracellular macrophage-generated NO [113]. On the other hand, under 
anaerobic growth, it utilizes internally generated NO as part of a bacterial metabolic 
pathway. NsrR is the major NO-responsive transcriptional regulator, repressing a small 
regulon of 4 genes.  As NO concentration increases, it is specifically inactivated, through 
the alteration of its iron-sulfur cluster, thus leading to up-regulation of denitrifying genes 
[114, 115]. 
Other transcriptional regulators. The LysR-type regulator CrgA is upregulated upon 
contact with human epithelial cells; it acts as a repressor of its own transcription and 
reportedly type IV pili subunits [46, 116, 117] and as an activator of the mdaB gene, 
coding for a hypothetical NADPH-quinone oxidoreductase [118].  
NMB0573 (annotated as AsnC) is a global regulator controlling the response to poor 
nutrient conditions, which are perceived by binding of this regulator to leucine and 
methionine, two amino acids representing general nutrient abundance [119].  
The Zinc uptake regulator (Zur) is a Fur-like regulator that responds specifically to Zn and 
controls Zn-uptake by regulating a TonB receptor that functions in high affinity Zn 
acquisition [120]. 
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1.4.3 The MarR family of transcriptional regulators 
The Multiple antibiotic resistance Regulator (MarR) family of transcriptional regulators is 
widely distributed throughout the bacterial and archaeal domains and it has been 
suggested that the MarR family is one of nine families of transcription factors to have 
evolved before the divergence of these domains over 3 billion years ago [121, 122]. 
MarR regulators include proteins critical for control of virulence factor production, 
bacterial response to antibiotics and oxidative stresses and catabolism of environmental 
aromatic compounds [122-125]. The eponymous protein MarR was originally 
characterized as the repressor of the multiple antibiotic resistance operon marAB in E. 
coli [126]. Typically, MarR-like regulators appear as homodimers and bind to relatively 
short palindromic or pseudopalindromic binding sites on DNA, consistent with their 
dimeric structure, although the lengths of the inverted repeats and the spacing between 
half-sites are variable. Members of the MarR family share the same core fold, in which 
each monomer consists of 6 α-elices and 2 β-strands (Figure 1.5).  
The N-terminal a-helix 1 and the C-terminal helices 5 and 6 interdigitate with the 
corresponding regions of the other subunit to form a dimerization domain, while the DNA 
binding domain is represented by wing helix motifs, spanning a-helix 3 and 4 and 
comprising b-strands 2 and 3. The two DNA binding lobes in the dimer contact the DNA in 
the major groove [125]. MarR regulators usually act as repressors, even if exceptions are 
reported, such as BadR from Rhodopseudomonas palustris which induces transcription of 
the badDEFG operon [127]. The majority of the MarR family members are regulated by 
the non-covalent binding of low-molecular-weight specific anionic lipophilic (usually 
phenolic) compounds. 
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Figure 1.5 - Typical structure of MarR transcriptional regulators. 
Structure of E.coli MarR dimer, showing the conserved domains of the family of transcriptional regulators. 
Modified from [128]. 
 
The interaction of ligands typically attenuates the ability of MarR dimers to bind their 
cognate DNA sequence, resulting in de-repression of transcription, but the opposite effect 
has also been reported [129]. Co-crystal structures of MarR homologs have been 
obtained with the molecule salicylate which, although a direct biological relevance may 
not be apparent, binds to numerous MarR homologs albeit at very high concentrations 
[128, 130-133]. The natural ligands for MarR proteins are often not known. The 
mechanism of ligand-mediated allosteric control of DNA binding is unique amongst 
prokaryotic transcriptional regulators in that the DNA and ligand binding domains almost 
completely overlap in the residues involved [125, 128].   
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Multiple mechanisms of repression have been described for MarR. The locations of the 
MarR binding sites often overlap the –35 and/or –10 promoter elements of their target 
genes, suggesting that repression is achieved by steric inhibition of RNA polymerase 
binding to the promoter. However, the homolog HpaR from E. coli likely represses 
transcription by blocking promoter escape by RNA polymerase, while SlyA from 
Salmonella typhimuriumhas been suggested to prevent open complex formation and the 
binding sites of other homologs suggest that they impede transcriptional elongation [134, 
135]. Cooperative binding to closely spaced recognition sequences has been 
demonstrated for OhrR from Bacillus subtilis and may occur for other MarR homologs, as 
well [136, 137].  
A MarR homolog has been characterized from N. gonorrhoeae that mediates the 
resistance of this organism to antimicrobial hydrophobic agents. The Fatty acids 
resistance Repressor (FarR) represses its own transcription and that of the distally located 
farAB operon, which encodes an efflux pump that exports host-derived antimicrobial 
agents such as long-chain fatty acids, by binding to three binding sites overlapping and 
upstream of the farAB promoter [138, 139].  
Two of the 36 putative transcriptional regulators in N. meningitidis are members of the 
MarR family and are encoded by the genes NMB1585 and NMB1843. The structure of the 
NMB1585-encoded protein has been resolved, and it was shown to bind to its own 
promoter DNA, but neither its target genes nor the signal to which it responds is known 
[140].  
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1.4.4 The Neisserial adhesin Regulator (NadR) 
The product of the NMB1843 gene is a MarR transcriptional regulator of 16.6 kDa per 
monomer and a homologue (with a nucleotide and amino acids sequences identity of 
>97% and >99%, respectively) of the gonococcal FarR, which was first described as a 
regulator of the farAB efflux pump that mediates gonococcal fatty acid resistance [138, 
139]. In contrast, fatty acid resistance is a high intrinsic feature of N. meningitidis, and a 
knockout of the NMB1843 gene was unchanged in its sensitivity to fatty acids, but 
adhered considerably more to epithelial cells than the wild type. Therefore, the NMB1843 
protein has been reported to play no role in regulating fatty acid and was, instead, 
demonstrated to repress expression of the meningococcal adhesin NadA [141, 142]. For 
this reason it was renamed Neisserial adhesin Regulator (NadR). 
The urogenital tracts colonized by gonococci are rich in hydrophobic compounds and 
these bacteria need to rely on active efflux systems for structurally diverse hydrophobic 
agents [143, 144]. In meningococci, NadR has evolved a different regulatory circuit, since 
efflux pumps became constitutively expressed. The nadA gene was acquired by horizontal 
gene transfer only by meningococci and, after this event, NadR has gained control over 
this meningococcus-specific surface protein involved in host colonization, thus 
contributing to divergent niche adaptation in pathogenic Neisseriae. 
As introduced above, nadA is phase variable due to a repeat sequence upstream of the 
nadA promoter region, which alters its expression by controlling the transcriptional 
activity of the promoter [145, 146]. NadR was demonstrated to be the major mediator of 
this control [141]. It binds with high affinity to two sequences flanking the variable repeat 
region and changes in the number of repeats affect the ability of NadR to repress the 
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nadA promoter [141]. As typical for MarR-like proteins, a small molecule ligand, 4-
hydroxyphenylacetic acid (4HPA), was identified which is able to relieve the DNA binding 
activity of NadR and derepress/induce nadA expression [141]. 4HPA is a catabolite of 
aromatic amino acids and is secreted in human saliva [147]. This metabolite may act as a 
relevant niche signal to meningococci present in the oropharynx, which is bathed in 
saliva, for the modulation of the activity of NadR. The structural bases of the 4HPA 
regulation of the NadR DNA binding activity are not clear and represent a topic of this 
thesis. 
NadR is highly conserved throughout all the Neisseria spp., while nadA is present only in 
few strains (see below). For this reason it is logical that NadR should regulate other target 
genes in addition to nadA. It has been described that, even if being a highly specialized 
repressor of nadA, NadR can regulate at lower extent other four genes during exponential 
growth phase [90]. The identification of genes that may be co-regulated with nadA by 
NadR, in response to signals that could have a biological relevance during pathogenesis of 
meningococcus, is part of the work of this thesis.  
 
1.5 Virulence factors and adhesins 
The virulence of N.meningitidis is influenced by multiple factors, comprising both the 
above mentioned genetic mechanisms, allowing the bacteria to vary its phenotype and 
adapt to the host, and iron sequestration mechanisms. Additionally, meningococci 
express multiple molecules acting as endotoxin, secreted factors or surface proteins, 
located in different compartment of the menincococcal cell membrane (Figure 1.6), which 
interact with host cellular molecule.  
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Capsule. The major virulence factor of N.meningitidis is the polysaccharide capsule, which 
plays a crucial role in meningococcal fitness, protecting the bacterium during airborne 
transmission between hosts [44, 148] and facilitating colonization and virulence by 
protecting the meningococcus from desiccation and the host innate and adaptive immune 
effector mechanisms such as phagocytic killing, opsonisation, antimicrobial peptides and 
complement-mediated bactericidal killing [149, 150]. Like many other virulence factors its 
expression is phase variable [47] and capsule switching between one serogroup to 
another provides a selective advantage that allows the bacterium to evade opsonisation 
or neutralization by natural or vaccine-induced protective anti-capsular antibodies [31]. 
Lipooligosaccharides (LOS). LOS are endotoxin and major constituent of the outer leaflet 
of the meningococcal outer membrane (OM), responsible for the physical integrity and 
proper functioning of the membrane and required for resistance of N. meningitidis to 
complement [151]. LOS comprises an inner and outer oligosaccharide core attached to 
the lipid A portion, that anchors the LOS into the outer leaflet of OM. Lipid A is 
responsible for the toxicity of LOS due to its ability to binds to different receptors on 
monocytic and dendritic cells triggering the secretion of various inflammation mediators 
and leading to endothelial damage, capillary leakage and septic shock [152, 153]. Phase 
and antigenic variations, leading to different saccharide chains, dramatically alter 
antigenic properties of LOS, enabling individual meningococci to display a repertoire of 
multiple LOS structures simultaneously [154].  
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Figure 1.6 - The meningococcal cell membrane. 
Cross sectional representation of the different compartments, composing the meningococcal membrane. 
Major virulence factors are shown and described in the text. From [4]. 
 
Pili. Pili are long filamentous structures consisting of protein subunits that extend from 
the bacterial surface beyond the capsule [155, 156]. Meningococcal pili belong to type IV 
pilus family, members of which undergo rapid extension and retraction. They represent 
the major contributor to adhesive property of the capsule and are involved in the 
initiation of the meningococcus-host cell interaction [157, 158]. In addition to adhesion, 
pili, are involved in several other functions, such as facilitating the uptake of foreign DNA 
from the extracellular environment, therefore increasing transformation frequency, a 
property that contributes to the virulence by promoting genetic adaptability [159]. 
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Twitching motility generated by pilus retraction is important for passage through the 
mucosal layer, movement over epithelial surface and micro-colonies formation [160]. The 
pilus is composed of identical subunits of pilin, expressed from the pilE locus. The pilE 
gene undergoes sequence variation due to homologous recombination with multiple non-
expressed truncated pilS genes, resulting in different adhesive and immunogenic pili 
variants [161].  
Opacity proteins (Opa and Opc). The opacity proteins (Opa and Opc) are integral outer 
membrane proteins that mediate pathogen-host interaction, adhering to and invading of 
epithelial and endothelial cells [156]. They are beta-barrel proteins, which vary in three of 
the four surface loops they possess [87]. Both bind the heparansulphate proteoglycans 
and sialic acids [162, 163]  but they also display a degree of receptor specificity for 
CEACAM (carcino-embryonic antigen-related cell-adhesion molecule), which are highly 
expressed during inflammation [164, 165]. 
Minor Adhesins. N. meningitidis has evolved a number of other surface structures that 
mediate interaction with host cells. Numerous apparently minor adhesins are generally 
expressed at low levels during in vitro growth but may be important in in vivo infections. 
It has been reported that in conditions that mimic the host infection such as iron [97] and 
oxygen limitation [106] or serum [166] and blood [167] the transcriptome of N. 
meningitidis is considerably altered and, as a result, some virulence factors may be over-
expressed. Furthermore, several adhesins are subject to antigenic variation and/or phase 
variation, which allow bacteria to generate a broad and variable repertoire of surface 
structure that facilitates evasion of immune effectors mechanisms and adaptation to 
different niche [44]. 
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Several minor adhesins belong to the family of autotransporter adhesin. Among them, 
Neisseria Hia homologue A (NhhA), mediates low levels of adhesion to epithelial cells and 
to extracellular matrix components as laminin and vitronectin [168]. More recent studies 
also support its contribution in colonization by preventing phagocytosis and complement 
attack [169]. Adhesion penetration protein (App), an autotransporter protein with a 
highly conserved aminoacid sequence, is present in all Neisseria species. It has been 
shown to mediate bacterial interaction to ephitelial cells during the early stages of 
colonization, before it is autocleaved. At later stages, App autocleavage may allow 
bacterial detachment, therefore facilitating bacterial spread [170]. Meningococcal serine 
protease A (MspA) is homologous to App and may also be cleaved and secreted. It is 
expressed by several but not all virulent Neisseria strains and mediates binding to both 
epithelial and endothelial cells and elicits the production of bactericidal antibodies [171]. 
The multiple adhesin family (Maf) is a family of glycolipid adhesins, characterised first in 
the gonococcus, which may play a role in Opa-independent cell invasion [172]. The 
neisserial adhesin A (NadA) is a subject of this thesis and will be discussed below in 
details. 
Porins. PorA and PorB, the most abundant proteins present in the outer membrane, are 
beta-barrel proteins which associate in trimers and function by creating pores for the 
passage of small hydrophilic solutes necessary for bacterial metabolism. PorA proteins are 
generally present in most meningococcal strains but their expression varies considerably 
[78, 173]. While not considered adhesins, they interact with numerous human cell and 
proteins [174], possibly having implication in pathogenesis and generation of an effective 
immune response. PorA elicits a protective immune response in humans [175, 176], while 
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the role of PorB in stimulating immune protection is less clear, being immunogenic [177] 
but poorly accessible for antibodies [178].   
Immune evading mechanisms. The ability to escape the elaborate machinery of the 
human immune system is a key determinant in the virulence of human pathogens. Many 
factors contribute to the virulence of N.meningitidis, involving mechanism to face 
antimicrobial peptides, reactive nitrogen and oxygen species, complement-mediated 
killing and, ultimately, the humoral and cellular components of the immune system. Efflux 
pump have been shown to have a critical contribution to antimicrobial peptide resistance 
[179]. Enzymes such as catalases (Kat), superoxide dismutase (SodB and SodC), nitrite 
reductase (AniA) and nitric oxide reductase (NorB) neutralize the toxic effects of 
neutrophilis and macrophages reactive oxygen and nitrogen species (ROS) [102, 113, 180, 
181]. Moreover, N. meningitidis uses a variety of mechanisms to survive to the 
bactericidal action of the complement system [150], involving the capsule, LOS and other 
factors. One such factor is the fHbp, which factor H (fH), the main inhibitor of the 
complement alternative pathway. Sequestering fH allows microbes to use this down-
regulator to limit complement activation on their surface. Neisserial Heparin-Binding 
Antigen (NHBA) has been described to bind heparin which may increase bacterial serum 
resistance due to the potential interactions of heparin with fH [182]. 
1.5.1 The Neisserial adhesin A (NadA) 
The Neisserial adhesin A (NadA) was firstly identified during a bioinformatic analysis of 
the genome of a virulent N. meningitidis B strain for finding novel vaccine candidates [62, 
183].  
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Structure. NadA is a surface-exposed member of the Oligomeric coiled-coil adhesin (Oca) 
family of bacterial Trimeric Autotransporter adhesins (TAs), such as YadA of Yersinia spp. 
[184-186], UspAs of Moraxella catarrhalis  [187, 188], Vomp proteins of Bartonella 
quintana [189], BadA of Bartonella henselae [190] and HadA of Haemophilus influenzae 
biogroup aegyptius [191]. All the TAs share an obligate trimeric architecture, formed by 
three identical inter-winded polypeptides. They are typically organized with a variable N-
terminal globular portion, called the passenger, projected into the external environment 
and comprising the binding site(s) for target cell receptors and a conserved C-terminal 
domain that drives the self-secretion and anchors the protein onto the bacterial outer 
membrane. These two domains are separated by a flexible coiled-coil stalk comprising a 
leucine zipper, which have a propensity to form trimers. The C-terminal anchor can form 
a barrel-shaped channel inserted into the outer membrane, which the passenger domain 
crosses during its delivery to the bacterial surface [192, 193]. NadA, as a member of this 
sub-group, is predicted to have a similar structure [194, 195], and the protein is 
characterized by a high degree of biochemical stability to heat, detergent and reduction 
[196]. 
Function. It has been shown that the NadA passenger mediates adhesion to human 
epithelial cells [197], suggesting a key role of NadA in bacterial adhesion to the naso- and 
oro-pharyngeal epithelia during meningococcal colonization of the human upper 
respiratory tract. NadA plays also a role in invasion of the mucosal epithelium as it has 
been demonstrated to mediate invasion into human epithelial cells [198]. Moreover, this 
protein is unique among TAs, being able to bind and activate macrophages [199] and 
dendritic cells [200]. As a consequence of this interaction NadA leads to the maturation of 
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dendritic cells as well as the activation and differentiation of monocytes into 
macrophages [199, 201]. In this sense NadA has a role in modulating the immune 
response after the crossing of the epithelial barrier, by targeting immune cells. NadA is 
capable of inducing strong cellular immune responses [202], bactericidal antibodies in 
animal models [183, 202-204] and in humans [205] as well as the secretion of pro-
inflammatory signals from monocytes and macrophages [199]. Recent studies indicate 
that part of the molecule can bind human β1 integrins [206] and extracellular chaperone 
human heat shock protein Hsp90 [207, 208]. These observations suggest NadA plays a 
multivalent role during the complex process of meningococcal infection which is not 
limited to bacterial adherence and invasion of mucosal epithelium, but includes 
translocation across the mucosal layer and release of chemokines by host dendritic cells, 
monocytes and macrophages recruited at bacterial entry sites. 
Classification and molecular epidemiology. The nadA gene is an independent genetic 
unit [203] and is the result of an insertion of foreign DNA in the meningococcal genome. 
The GC content of the NadA region is lower than the chromosome, which suggests 
acquisition by horizontal gene transfer and subsequent limited evolution to generate five 
variants, each of them including a number of subvariants [203, 209, 210]. NadA-1, -2, -3 
and -5 occur in invasive strains, whereas NadA-4 has only been found in strains associated 
with nasopharyngeal carriage.  
NadA is a risk factor for the development of meningococcal disease, as it is present in 50% 
of the disease-associated strains and overrepresented, almost 100%, in hypervirulent 
meningococcal lineages (clonal complexes ST-32, ST-8, ST-11, ST-1157 and ST-213) [210-
213]. All together, the nadA gene is carried by about 30% of pathogenic isolates collected 
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from patients in 5 European countries and the US [211-213]. Only 5% of carriage isolates 
obtained from healthy individuals harbour the gene [210], furthermore, nadA is absent 
from N. gonorrhoeae and the commensal N.lactamica and N. cinerea isolates. 
Regulation and expression. The nadA gene shows growth phase dependent expression, 
reaching a maximal level in the stationary phase [141, 203, 214]. As mentioned above the 
expression of nadA is also subject to phase variation, through the presence of a variable 
length tetranucleotide repeat upstream of its promoter [141, 145]. For this reason nadA 
expression varies both between different strains, as well as within a single strain, having 
variants where changes in the repeats number result in promoters with low, medium or 
high activity [141, 145]. However, the major mediator of the phase variable expression of 
nadA is NadR, which binds to two high affinity sites flanking the tetranucleotide repeat. 
One operator overlaps the -10 region of the promoter and the transcriptional start site, 
therefore binding of NadR is consistent with its function as a repressor through sterically 
hindering RNA polymerase to access to the promoter. The other high affinity operator is 
on the distal upstream side. The DNA bending protein, Integration Host Factor (IHF), also 
binds on a single binding site that is located between the two high affinity NadR 
operators. The ability of IHF to bend DNA may facilitate the looping of the DNA of the 
nadA promoter and bring the distal operator near to the core promoter elements, 
possibly leading to interactions of NadR dimers present on spatially proximal operators in 
a mechanism similar to the one described for the lac operon [215, 216] and purposed for 
the gonococcal FarR on the farAB promoter [138]. The alpha-subunit of RNA polymerase 
binds to the distal NadR operator and also immediately upstream of the core promoter 
overlapping the TAAA tract which may function as UP-like elements. A model for nadA 
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regulation has been proposed in which differential distancing between the NadR 
operators and the contact points of RNA polymerase result in optimal or suboptimal 
configuration of the protein complexes and, therefore, in efficient or inefficient NadR-
mediated repression and cis-enhancement of RNA polymerase activity on the basal 
promoter strength [141], (Figure 1.7).  
The 4HPA molecule, a catabolite of aromatic amino acids which is commonly found in 
human saliva [147], is able to induce nadA expression by alleviating the NadR-mediated 
repression, suggesting that NadA may be induced in the mucosal niche which is bathed in 
saliva, during infection [141]. Moreover, anti-NadA antibodies have been found in sera of 
young children (age 0.2–4.0 years) convalescing after meningococcal disease, suggesting 
that during invasive human infection NadA is expressed to an immunogenic level which is 
sufficient to drive a robust humoral response during infection [205]. 
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Figure 1.7 - Model of the nadA promoter regulation. 
Two promoter variants with 9 and 8 repeats representing low activity and high activity promoter phase 
variants, respectively, highlighting the ability of NadR to efficiently or less efficiently repress the promoters 
(top panels) and NadR-independent effects on the derepressed promoter basal levels possibly due to 
differential contacts with the α-subunit of RNAP (bottom panels) due to different spatial organization of the 
NadR and RNA polymerase contact points resulting from the different number of repeats. From [141].  
 
1.6 Meningococcal vaccines  
Meningococcal disease progresses rapidly and in its early stages it is easily misdiagnosed 
[4, 6], making vaccination the best public health option worldwide and the most effective 
way to prevent it. No broadly protective vaccine is currently available to provide 
protection against all serogroups of N. meningitidis. For four of the five disease-
associated serogroups A, C, W and Y, capsular polysaccharides have been successfully 
used as antigens to produce polysaccharide and glycoconjugate vaccines, which are 
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currently in use. Quadrivalent vaccines against serogroups A, C, W  and Y include the 
conjugate vaccines Menactra (Sanofi Pasteur) and Menveo (Novartis), and the 
polysaccharide vaccine Menomune (Sanofi Pasteur), Mencevax (GlaxoSmithKline) and 
NmVac4-A/C/Y/W-135 (JN-International Medical Corporation) [217]. A vaccine called 
MenAfriVac has been developed through a program called the Meningitis Vaccine Project 
to prevent meningitis group A infections in the ‘meningitidis belt’ [218]. 
The use of capsular polysaccharide as the basis of a vaccine for prevention of serogroup B 
strains (MenB) diseases has been problematic. A capsular polysaccharide of MenB is 
identical to a widely distributed human carbohydrate (α[2-8]N-acetylneuraminic acid or 
polysialic acid), which, being a self-antigen, is a poor immunogen in humans and may 
elicit autoantibodies [219, 220]. In addition, as mentioned above, the most represented 
surface exposed protein, PorA and Opa, which should be used as antigens, show 
sequence and antigenic variability and poor conservation between the diverse strains that 
cause endemic MenB disease. As a result of these limitations, the only currently available 
MenB vaccines are the “tailor made” outer membrane vesicle (OMV) vaccines, that have 
been developed and successfully used to control epidemics that have primarily been 
caused by a single strain [176]. Although effective, the limitation of the OMV vaccines is 
that they are strain-specific vaccines and can be used against clonal disease outbreaks but 
not for prevention of sporadic disease caused by heterologous strains. OMV vaccines 
have proved to be effective and have been used in Norway [221], Cuba [222], Chile [223] 
and New Zealand [224] to disrupt homologous strain outbreaks.  
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1.6.1 Reverse vaccinology and the 4CMenB vaccine 
The availability of whole genome sequences in the genomic era has radically changed the 
approach to vaccine development. To overcome the problems regarding the production 
of a MenB vaccine, an in-silico genome-based approach, called Reverse Vaccinology 
(Figure 1.8) has been used, allowing the identification of approximately 600 open reading 
frames that were likely to encode potentially surface exposed proteins in the MenB strain 
MC58 [183]. The candidate antigens sequences were analysed for their conservation 
among a wide range of MenB strains and expressed as recombinant protein in E.coli to 
test their surface localization and ability of inducing bactericidal antibodies in mice.  This 
analyses revealed more than 90 previously unknown surface-located proteins, 29 of 
which were able to induce bactericidal antibodies, the favourites of which were selected 
for further studies [203, 225-228]. 
This approach has led to the development of a novel four component recombinant 
protein vaccine against MenB named 4CMenB [204, 229]. 4CMenB has progressed 
through clinical trials that have demonstrated its safety [230, 231] and its efficacy in 
inducing a protective immune response in infants, children, adolescents and adults 
against potentially the majority of MenB strains [232, 233]. The 4CMenB vaccine contains 
five Genome-derived Neisseria Antigens (GNA), which are formulated as one single 
recombinant protein, the Neisserial adhesin A (NadA) [198, 203], and two recombinant 
fusion proteins, the factor H binding protein (fHbp) [234, 235] and Neisserial Heparin-
Binding Antigen (NHBA) [182, 226] fused with meningococcal gene products GNA2091 
and GNA1030, respectively. NadA, fHbp and NHBA are the major antigens that were 
selected through reverse vaccinology, based on their ability to induce broad protection 
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inferred by serum bactericidal activity (SBA) assays or observed in passive protection in 
the infant rat or mouse protection assays [204]. GNA2091 and GNA1030 are two 
accessory antigens, well conserved in N. meningitidis strains but less well functionally 
characterized than the major antigens. They are included in 4CMenB formulation as the 
fusion proteins induce more potent immune responses in SBA than the individual antigen 
[204]. The vaccine also contains Outer Membrane Vesicles (OMVs) from the 
meningococcus B strain NZ98/254 in which PorA serosubtype 1.4 represents the major 
antigen [236]. 
 
 
Figure 1.8 - Reverse vaccinology. 
The process of reverse vaccinology applied to the development of the 4CMenB vaccine is schematized here 
and described in details in the text.  
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1.6.2 Vaccine coverage prediction 
The studies performed by Goldschneider in 1969 demonstrated that the presence of 
bactericidal antibodies in the serum, assessed by serum bactericidal assay with human 
complement (hSBA), correlates with resistance to meningococcal meningitis. Therefore, 
hSBA is widely accepted as a surrogate marker of protection against meningococcal 
disease [12, 237-239]. hSBA assay made possible the development of meningococcal 
vaccines based initially on the serogroup A, C, Y and W capsular polysaccharides, and 
later, on these same polysaccharides covalently conjugated to protein carriers [240-242].  
However, using hSBA in measuring the potential effectiveness of the 4CMenB vaccine to 
kill circulating serogroup B strains presents two problems: on one hand, it requires 
performing the assay against many diverse strains for each geographic region, which is 
impractical, especially for infants, where serum volumes are very limited, on the other 
hand the hSBA reflects the cumulative effect of all of the antibodies present in a serum 
sample in killing the bacteria, making it dificult to understand the contribution of each 
individual antigen to the function of the four component 4CMenB vaccine.  
In order to overcome these issues and predict the coverage of 4CMenB, and a novel assay 
has been developed, the Meningococcal Antigen Typing System (MATS) [243], (Figure 
1.9). MATS assesses simultaneously the antigenic cross-reactivity and the level of 
expression of the antigens present on the surface of an unknown meningococcal isolate 
with respect to reference MenB strains for a specific antigen. MATS uses ELISA assays to 
measure the three 4CMenB vaccine recombinant antigens NadA, fHbp, and NHBA. The 
output value is the MATS Relative Potency (RP), which correlates with the hSBA assay and 
may predict whether a strain would be killed due to antibodies elicited by the 4CMenB 
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vaccine. MATS RP threshold values for complement-mediated killing of MenB by 
antibodies against NadA, fHbp and NHBA antigens was established and termed the 
Positive Bactericidal Threshold (PBT), for each specific antigen. Regarding PorA, the MATS 
determines the PorA subtype by serological analysis or by PCR sequencing and strains 
that carry the P1.4 PorA subtype are considered killed by vaccine-induced immune sera. 
 MATS can be easily performed in large panel of strains, making it possible to survey large 
collections of MenB isolates in order to determine the potential for strain coverage by the 
4CMenB vaccine of a target geographic region [244, 245]. Currently MATS is being used 
by several meningococcal reference laboratories to establish the potential coverage of 
the 4CMenB vaccine in different countries in Europe, North and South America and 
Australia. According to MATS, it has been estimated that 78% of circulating MenB strains 
in five European countries would have at least one antigen rated above the PBT and 
therefore would be covered by the 4CMenB vaccine. However, the estimated 
contribution of the NadA antigen to the vaccine coverage would comprise only about 2% 
of the tested strains [246, 247]. Currently, the amount of the 4CMenB antigens expressed 
by meningococci during human pathogenesis is unknown, but accurate estimates are 
important to evaluate the real effectiveness of the vaccine. The study of NadA expression 
during host infection and its implication on vaccine coverage prediction are a focus of this 
thesis. 
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Figure 1.9 - Schematic of the MATS ELISA method. 
(A) MenB bacteria are grown overnight on chocolate agar. (B) A suspension of bacteria taken from the plate 
is prepared to a specified OD600. (C) Detergent is added to the suspension to extract the capsule and 
expose the antigens. (D) Serial dilutions of extract are tested in the MATS ELISA. A specific capture antibody 
(yellow) binds one of the antigens (example: fHbp, blue) from the extract, which is then detected with a 
specific biotin-labeled antibody (yellow and purple) and a streptavidin–enzyme conjugate (green and gold). 
(E) Plates are read at 490 nm in an ELISA reader. (F) Results are calculated by comparing the curve of OD490 
vs. dilution obtained with the serially diluted unknown strain to a serially diluted reference strain tested in 
the same ELISA plate. From [243]. 
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2 RESULTS 
2.1  In the NadR regulon, adhesins and diverse meningococcal functions 
are regulated in response to signals in human saliva 
The meningococcal NadR was shown to repress expression of the NadA adhesin and play 
a major role in NadA phase variable expression [141]. However, while nadA is present in 
about 30% of circulating strains, NadR is always present and well conserved in all 
meningococcal genomes available.  
The aim of this part of the thesis is to clarify the global role of NadR during menincoccal 
pathogenesis. We wish to elucidate the NadR regulon by finding its gene targets and the 
kind of regulation mediated on them. We would also like to understand how the NadR 
activity is affected by the 4HPA molecule, that is present in saliva and, therefore, in the 
niche of meningococcal colonization, and which was previously shown to induce nadA 
expression [141].   
 
2.1.1 Global analysis of gene expression in the NadR mutant 
In order to identify NadR-regulated genes in N. meningitidis we used a custom-made 
Agilent oligonucleotide microarray to compare the transcriptional profiles of MC58 wild 
type and MC-∆1843 NadR mutant strains grown until mid-log phase. Three independent 
2-colour microarray experiments were performed comparing pooled RNA from triplicate 
cultures of each strain, as well as three dye-swap experiments. The results obtained from 
these experiments were averaged after slide normalization and 28 differentially 
expressed genes were identified with a log2 ratio >0.9 transcriptional change and a t-test 
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statistics p-value ≤ 0.01 (Table 2.1.1).  When we reduce the criterion to log2 ratio >0.6 in 
the original 3 experiments (excluding the dye-swap) we can select another 9 differentially 
up regulated genes in the NadR mutant with a p-value ≤ 0.01 (Table 2.1.1). RT-PCR 
analyses were consistent with the microarray data (Table 2.1.1) confirming the putative 
NadR-regulated genes identified in this global gene expression analysis. 31 genes were 
up-regulated, whereas 6 were down-regulated in the NadR mutant. The contiguous genes 
that are in the same orientation and exhibiting similar regulation have been grouped into 
likely operons (Table 2.1.1).  
In order to confirm that the regulation is NadR dependent, we complemented the MC-
∆1843 mutant by reintroducing the nadR gene under the control of an inducible Ptac 
promoter in a different locus in the genome, generating the strain ∆NadR_C. By altering 
the concentration of IPTG in the growth medium of the ∆NadR_C strain, we obtained a 
level of NadR expression in the complemented strain comparable to that of the wildtype 
(data not shown) and prepared total RNA from this strain in the same condition as the 
microarrays experiments. We measured the transcriptional levels of the target genes by 
RT-PCR in the complemented ∆NadR_C strain and observed that for all of the genes 
tested that were up-regulated in MC-∆NadR (MC-∆NadR vs MC58), complementation of 
the mutant (NadR_C vs MC58) restored their expression to levels similar or slightly lower 
than the wild type level. In contrast, none of the down-regulated genes was restored to 
wild type through complementation of the mutant, suggesting that these effects were not 
dependent on the activity of the NadR protein. Among the 6 down-regulated genes 
NMB1844, NMB1842 and NMB1841 are contiguous and in the same orientation to the 
NadR-encoding gene NMB1843 and may be polarly affected by the insertion of the 
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antibiotic resistance cassette for the generation of the mutant. The lack of 
complementation of deregulation of NMB0119 and NMB0120 is instead likely to be due 
to a nadR-independent effect such as phase variation or secondary mutations.  
These data suggest that NadR functions solely as a repressor protein, negatively 
regulating multiple loci. Through global gene analysis we identify at least 18 hypothetical 
operons/transcriptional units coding for 31 genes whose expression was repressed by the 
nadR gene (Figure 2.1.1). 
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Table 2.1.1. Differentially regulated genes in NadR null mutant 
   Microarray results 
∆1843 vs MC58wt RT-PCR Fold change 
 
Gene Name OriA Function Average
B 
(Fold Change) Pval 
∆1843 vs 
MC58 
NadR_C vs 
∆1843 Gel shift 
NMB0119 ↑ hypothetical protein -4.5 1.8E-14 -2.7 1.1  
NMB0120 | hypothetical protein -8.4 2.3E-06 -4.4 1.1 nd 
NMB0207 ↓ glyceraldehyde 3-phosphate dehydrogenase, gapA 4.0 8.5E-07 5.4 -5.9 + 
NMB0375 | MafA1 adhesin, mafA1 2.1 4.4E-05 2.3 -2.3 + 
NMB0374D ↓ MafB1 adhesin, mafB1 1.3 4.7E-02 nd nd  
NMB0401 ↓ proline dehydrogenase, putA 1.9 1.2E-04 2.4 -3.1 + 
NMB0429 | hypothetical protein, putative regulatory protein 1.9 3.1E-06 nd nd + 
NMB0430 | putative carboxyphosphonoenolpyruvate 
phosphonomutase, prpB 1.9 9.6E-04 
nd nd  
NMB0431 ↓ methylcitrate synthase/citrate synthase 2, prpC 1.9 1.6E-04 nd nd  
NMB0652 | MafA2 adhesin, mafA2 2.0 1.4E-04 2.3 -2.3 + 
NMB0653 | MafB-related protein, mafB2 1.9 6.8E-07 nd nd  
NMB0654 ↓ hypothetical protein 2.1 3.6E-03 nd nd  
NMB0865 ↑ hypothetical protein 1.9 4.0E-05 2.8 -5.5 nd 
NMB0866 | hypothetical protein 2.0 8.9E-03 nd nd  
NMB0955 | 2-oxoglutarate dehydrogenase, E1 component, sucA 1.9 2.7E-07 2.9 -3.2 + 
NMB0956D ↓ 2-oxoglutarate dehydrogenase, sucB 1.6 2.7E-02 nd nd  
NMB1205 ↓ hypothetical protein 2.4 8.4E-04 nd nd + 
NMB1277 ↑ transporter, BCCT family 1.9 1.2E-06 1.7 -4.5 + 
NMB1299 ↓ sodium- and chloride-dependent transporter 2.2 3.2E-03 nd nd - 
NMB1476 ↑ glutamate dehydrogenase, NAD-specific, gluD 4.1 2.3E-11 7.9 -11.1 + 
NMB1477 | hypothetical protein, comA competence protein 2.3 7.0E-03 nd nd  
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NMB1478 | phosphoglycolate phosphatase 2.3 3.6E-05 3.7 -2.6 - 
NMB1479 ↓ regulatory protein RecX 2.2 2.1E-06 nd nd  
NMB1841 ↑ mannose-1-phosphate guanyltransferase-related 
protein -8.5 1.1E-16 
-3.8 1.0  
NMB1842 | putative 4-hydroxyphenylacetate 3-hydroxylase -14.1 0.0E+00 -5.6 0.9  
NMB1843 | transcriptional regulator -25.5 8.3E-09 -12.3 nd + 
NMB1844 | hypothetical protein -3.0 4.3E-06 -1.6 1.1 - 
NMB1994 ↓ putative adhesin/invasin, nadA 59.6 0.0E+00 97.3 -133 + 
   AverageC Pval    
NMB0535 ↓ glucose/galactose transporter, gluP 1.9 3.6E-04 nd nd - 
NMB0702 ↓ competence protein ComA 1.8 1.1E-03 1.9 -7.1 - 
NMB0978 ↑ NAD(P) transhydrogenase, beta subunit, pntB 1.7 6.4E-03 4.3 -2.9  
NMB0979* | Hypothetical protein 1.6 1.3E-01 nd nd  
NMB0980* | NAD(P) transhydrogenase, alpha subunit, pntA 1.6 2.8E-02 1.8 -1.2 + 
NMB1609 ↑ trans-sulfuration enzyme family protein, metZ O-
succinylhomoserine sulfhydrolase 1.7 2.2E-06 
2.3 -4.0 + 
NMB2097 ↑ hypothetical protein, pykA pyruvate kinase 1.5 2.0E-04 nd nd  
NMB2098 | conserved hypothetical protein 1.6 4.1E-03 nd nd  
NMB2099 | conserved hypothetical protein, putative 5-
formyltetrahydrofolate cyclo-ligase 1.7 4.7E-03 
2.4 -4.3 + 
A Ori: orientation. Genes are grouped into likely operons as predicted by their similar orientation and proximity. Vertical solid lines represent the first and following 
genes in the predicted operon. Arrows pointing up represent the last gene in the operon in the reverse strand of the genome. Arrows pointing down represent the last 
gene in the operon in the forward strand of the genome. 
B Average values of three separate microarray experiments and three dye-swap experiments. 
C Average values of three separate microarray experiments. 
D Genes with values outside the criteria used are included when contiguous and oriented similarly to upstream or downstream co-regulated genes. 
E ND, not determined.
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2.1.2 Functional classification of the NadR-regulated genes 
Among all NadR-regulated genes (Figure 2.1.1), the NadA adhesin shows the most altered 
expression profile in the ∆1843 mutant. Interestingly, 2 of the 3 mafA (multiple adhesin 
family A) loci were also repressed by NadR. The NadR-regulated MafA1 and MafA2 
(encoded by NMB0375 and NMB0652) are expressed in MC58, while mafA3 is a 
pseudogene containing a frameshift. The maf loci, similarly to the locus of the Type IV pili, 
consist of downstream silent cassettes of the expressed genes and are thought to 
undergo antigenic variation through recombination of the coding sequences with the 
silent cassettes [71]. The maf genes encode a family of variable lipoproteins originally 
identified as glycolipid-binding proteins in pathogenic Neisseria [71, 248, 249], which have 
been shown to adhere to glycolipid receptors on human cells [250, 251], and thus 
predicted to be adhesins. While only approximately 40% of circulating meningococcal 
strains carry the nadA gene, which is thought to have been acquired by horizontal gene 
transfer, all meningococcus strains carry multiple loci expressing the Maf adhesins.  
In addition to outer membrane adhesins, NadR is able to repress the expression of a 
number of genes coding for inner membrane transporters including those involved in 
transport of sugars (NMB0535, glucose/galactose transporter), compatible solutes 
(NMB1277, encoding a putative glycine betaine transporter), transporters of unknown 
substrates (NMB1299, encoding an Na- and Cl-dependent transporter) and even DNA 
(NMB0702, encoding the ComA protein). NadR also regulates genes involved in energy 
metabolic pathways including the NMB0401 (putA encoding proline dehydrogenase), 
NMB1476 (gluD encoding glutamate dehydrogenase) and NMB0955-957 (sucAB-lpdA1 
encoding 2-oxoglutarate dehydrogenase) genes involved in sequential steps of L-proline 
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and glutamate catabolism, along with other genes that may be involved in amino acid 
metabolism (NMB1609, NMB1842), and other energy metabolic processes (NMB0207, 
gapA-1 encoding a glyceraldehyde 3-phosphate dehydrogenase; NMB0430-431 coding for 
a putative 2-methylcitrate pathway; NMB1478, gph encoding phosphoglycolate 
phosphatase; and NMB0978-980, pntAB encoding NAD(P) transhydrogenase) as well as a 
number of hypothetical genes (NMB0865/0866, NMB1477, NMB2099-2097) whose 
function is unknown. Included also in the list are two possible regulators of gene 
expression: NMB1479, coding for a putative transcriptional regulator, and NMB1205, 
which synthesizes a small non-coding regulatory RNA recently named AniS [252].  
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Figure 2.1.1 – Functional classification of the NadR direct and indirect regulated genes. 
(A) The diagram shows the numbers of genes in the NadR regulon divided according to their functional 
classification. Percentages of the total genes in the regulon are reported for each functional class. (B) 
Schematic representation of the loci controlled by NadR, clustered according to their functional 
classification. Directly NadR bound targets have been identified through EMSA analyses and indicated by a 
red box at the 5’ of the ORF.  
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2.1.3 Binding of NadR to its targets 
It has been previously demonstrated that NadR binds to the nadA and farAB promoter 
regions [141, 253], although no transcriptional regulation of farAB is thought to occur in 
meningococcus [253]. Moreover, it has been recently reported that NadR-regulated 
genes were not directly bound by the protein [90], suggesting an indirect NadR 
regulation. To determine which of the NadR-repressed genes are under direct regulation 
of NadR, we amplified by PCR the upstream promoter regions of identified target genes 
and performed gel-shift analysis with purified recombinant NadR. We found that out of 
19 target promoter regions tested, 14 are bound by the NadR recombinant protein (Table 
2.1.1 and Figure 2.1.1B). Interestingly, NadR binds its own promoter, suggesting a 
possible auto-regulation. The five promoter regions not directly bound by NadR were 
those of NMB0535, NMB0702, NMB1299, NMB1844 and gph (NMB1478), although we 
cannot exclude that the promoters and therefore NadR regulatory sites are further 
upstream than the regions tested.  
In order to demonstrate the specificity of NadR binding on its targets, a gel shift 
experiment on the promoter region of NMB0401/putA was performed in the presence of 
increasing concentration of sonicated salmon sperm DNA (non-specific competitor) or 
cold putA promoter (specific competitor) (Figure 2.1.2A).  
One slow migrating radioactive complex is formed by adding approx 3 nM of NadR 
protein to the labeled putA promoter. A second complex appears by increasing the 
concentration of NadR to 12.5 nM. 1-fold of cold putA promoter probe is sufficient to 
abolish the higher complex and 5-fold completely prevents the binding of NadR to the 
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labeled probe. Instead, up to 25-fold of non-specific competitor had no effect on protein-
DNA complex formation, showing that NadR binds specifically to this promoter gene.   
A panel of representative gel shift experiments from Table 2.1.1 is shown in Figure 2.1.2B. 
All these gel shifts were performed in the presence of more than 10-fold excess of non-
specific competitor DNA in order to avoid non-specific NadR binding. It is worth noting 
that with the exception of the promoter regions of NMB0375 (Figure 2.1.2B) and 
NMB0652 (data not shown) genes, coding for MafA1 and MafA2 respectively, all other 
promoters exhibit multiple DNA-protein complexes, and therefore are likely to contain 
multiple binding sites for NadR.  
We conclude that NadR can bind to the upstream promoter region in vitro of at least 14 
transcriptional units consisting of 26 genes, confirming that these genes are members of 
the NadR regulon. NadR regulation of the other genes may occur through indirect 
mechanisms such as the regulation of an intermediate regulating factor. 
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Figure 2.1.2 - NadR binds to its target genes in a specific way.  
(A) Gelshift analysis of NMB0401/putA promoter region. In the left panel 40 fmols of labeled probe was 
incubated with increasing amounts of NadR protein corresponding to the indicated concentrations. To test 
the specificity of NadR binding at the NMB0401 promoter region, in the right panel the same amount of 
probe was incubated either without or with increasing amount of non-specific (sonicated salmon sperm 
DNA) or specific competitor DNA (not labeled NMB0401 promoter probe) , in presence of the indicated 
concentrations of NadR protein. (B) A representative panel of gelshift experiments reported in Table 1 is 
shown. Promoter regions of indicated targets were amplified by PCR and radioactively end-labeled. 40 
fmols of labeled probe was incubated with 2 μg of non-specific competitor DNA and increasing amounts of 
NadR. Asterisks indicate free probes and arrows indicate DNA-protein complexes. 
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2.1.4 The NadR target genes can be classified in two types regarding their 
promoter architecture  
The previously described promoter region of nadA includes two distally spaced high 
affinity binding sites for NadR (named OpI and OpII) and one with lower affinity 
interposing the others (named OpIII) ([141] and schematic representation in Figure 
2.1.3B). The presence of multiple NadR binding sites was suggested by gelshift analysis on 
all NadR identified targets except for NMB0375 and NMB0652. To better understand 
possible differences between promoter architectures of NadR regulated genes we 
performed DNase I footprint analysis of NadR purified protein on a representative panel 
of promoter regions (Figure 2.1.3A).  
Both the promoter region of nadR/NMB1843 and putA/NMB0401 display two distally 
spaced NadR protected regions, one overlapping the predicted promoter sequences and 
the second distally upstream. This promoter architecture is comparable to the well-
known promoter region of NadA (Figure 2.1.3B) where the OpII overlaps the –10 box of 
the promoter and the OpI is distally spaced. On the other hand, the promoter region of 
mafA1/NMB0375 (Figure 2.1.3A and schematic representation in Figure 2.1.3B) 
comprises only one binding site for NadR which overlaps the +1 and downstream of the 
promoter. 
Taken together these data suggest the existence of two types of promoter architecture 
for NadR regulated genes: type I genes, including nadA and the majority of genes of the 
regulon, have multiple NadR binding sites and in particular two high affinity sites, one 
overlapping the promoter (centered at -4, -19 and -13 position for nadA, nadR and putA, 
respectively) and one distally upstream (centered at -129, -103 and -79, respectively); 
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type II genes, including the mafA coding genes NMB0375 and NMB0652, have one single 
NadR binding site centered at the +7 position of the promoter region.  
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Figure 2.1.3 - Type I and type II genes have different promoter architectures.  
(A) DNase I footprint analyses of NadR on a representative panel of the promoter regions of its target 
genes. 40 fmol of each probe were incubated with increasing amount of NadR purified protein as indicated 
and then cleaved with DNase I. Regions of protection are indicated with vertical unbroken lines. Regions of 
non-specific protection, possibly due to multimerization of NadR purified protein, are indicated with vertical 
dotted lines. Hypersensitive bands are marked by a head arrow; protected disappearing bands are indicated 
with asterisks. The predicted +1, -10 and -35 of each promoter region were deduced from the DNA 
sequences and are properly located with respect to the G+A sequences. The positions of NadR protected 
regions are also indicated. Two classes of promoter architectures are indicated as type I and type II. (B) 
Schematic representations of type I and type II promoter regions. The structure of the nadA promoter is 
reported as previously described [146], [145] and [141]. The low affinity operator III (Op III) at the TAAA 
repeats tract is represented by a dark grey box. Regions bound and protected by NadR in DNase I footprint 
analysis are represented by black boxes. The putative +1 of putA, nadR mafA1/2 promoters are shown. The 
centre of each NadR binding site is reported as well. DR, direct repeat (border of region of horizontal 
transfer).  
 
2.1.5 Ligand-responsive regulation of NadR target genes expression by 4HPA 
We have previously shown that a small molecule, 4-hydroxyphenylacetic acid (4HPA), 
regulates NadR-mediated repression of NadA expression in meningococcus [141]. 
Therefore, we investigated the 4HPA-responsive regulation of the genes belonging to the 
NadR regulon. To understand the in vivo effect of the small molecule on target gene 
expression, we quantitatively analyzed the transcriptional level of selected target genes in 
the MC58 wild type and NadR null mutant in the presence or absence of 5 mM 4HPA, 
using RT-PCR (Figure 2.1.4). Surprisingly, we found that not all targets respond in a similar 
fashion to the 4HPA inducer molecule and two classes of gene targets could be defined, 
corresponding to the two types of genes identified due to their promoter region 
architectures. We found that the expression of most genes was induced by the 4HPA 
molecule (type I genes), either partially (i.e. nadA) or fully (i.e. putA, gph, nmb1277) with 
respect to the maximal derepression achieved in the NadR mutant. Intriguingly, we found 
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that only mafA genes (type II genes) expression responds in the opposite way to 4HPA, 
with mafA transcription being repressed in the presence of 4HPA and suggesting that this 
small molecule acts as a co-repressor of NadR at the mafA1 and mafA2 promoters. In the 
NadR mutant strain 4HPA-dependent regulation is largely absent indicating that NadR is 
the mediator of the 4HPA transcriptional responses. 
This analysis suggests that while NadR represses all genes in its regulon, 4HPA may act as 
an inducer (type I genes) or a co-repressor (type II genes), resulting in alternative NadR-
mediated responses in vivo, which can be at least partially due to the differential 
promoter architectures of the two types of NadR targets. 
 
 
Figure 2.1.4 - Effect of 4HPA on gene expression. 
RT-PCR analysis of NadR target transcripts in total RNA prepared from the wildtype (MC58) and MC-∆NadR 
mutant strains (∆NadR) after growth in the presence or absence of 5 mM 4HPA. RT-PCR was performed in 
duplicate on three independent biological replicates and the average values are shown. The primers used in 
qRT-PCR for mafA1 and mafA2 genes cannot distinguish between the NMB0375 and NMB0652 genes as the 
sequences are identical. Two types of transcriptional patterns can be detected, type I (4HPA-induced) and 
type II (4HPA-repressed). 
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2.1.6 The NadR-dependent regulation of NadA, MafA and NadR itself is common 
among meningococcal strains 
In order to investigate whether NadR-dependent regulation of NadA and MafA protein 
expression was exhibited by other strains, we extended our studies to a larger panel of 
meningococcal strains. Western blot analysis were carried out on the wild type and their 
respective NadR mutant strains grown in the presence or absence of 4HPA (Figure 2.1.5). 
Expression of NadA and MafA is variable between strains, while NadR is expressed to 
essentially the same level (lanes 1). All NadR null mutants exhibited higher levels of NadA 
and MafA than their respective wild types (lanes 3 versus 1) confirming the NadR 
repression of both nadA and mafA genes. In all the wild type strains, the 4HPA molecule 
results in induction of both NadA and, to a lesser extent, NadR and co-repression of MafA 
(lanes 2 versus 1), while it had no effect on NadA or MafA expression in the NadR mutants 
(lanes 4 versus 3), indicating that the effects of 4HPA are NadR-dependent. 
Taken together, these results suggest that both the NadR-dependent regulation of NadA 
and MafA and the 4HPA activity as an inducer of nadA and a co-repressor of mafA are not 
restricted to the MC58 strain but are common throughout different meningococci. 
Furthermore, it would appear that the level of NadR itself is induced by 4HPA, most 
probably through alleviation of autoregulatory repression of its own promoter. 
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Figure 2.1.5 - NadR-regulated adhesins responses in a broad panel of meningococcal strains. 
Western blot of wildtype (lanes 1 and 2) and corresponding NadR knockout (lanes 3 and 4) cultures of the 
indicated strains grown in the presence (lanes 2 and 4) and absence (lanes 1 and 3) of 1 mM 4HPA as 
indicated, showing NadA, MafA and NadR expression. The NadA protein migrated at a molecular weight of 
98 kDa and corresponds to the trimeric form of the protein [203] and the MafA band migrates at 36 kDa 
and corresponds to both MafA1 and MafA2 proteins coded for by the NMB0375 and NMB0652 genes 
whose sequences are 100 % identical. This band is absent in Western blots of extracts from the NMB0375 
and NMB0652 double mutant [254] (data not shown). A non-specific band indicated with an asterisk is 
reported as a loading control. 
 
2.1.7 Incubation with human saliva has the same effect on NadA and MafA 
expression as 4HPA 
It has been previously demonstrated that the 4HPA molecule is a catabolite of aromatic 
amino acids secreted in human saliva [147]. To test whether the effects due to 4HPA in 
vitro may have biological relevance we tried to achieve similar results with human saliva. 
Mid log cultures of MC58 were incubated for 1 hour either with 4HPA or with increasing 
amount of human saliva from three different donors. Total protein extracts were 
obtained and the expression levels of NadA and MafA were analyzed by Western blot 
(Figure 2.1.6A). The Western blots show the induction of NadA and the repression of 
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MafA following incubation with 4HPA (compare lanes 2 to 1 of each blot) and, even if 
with much greater experimental variability, the same results are obtained following 
incubation with increasing concentration of human saliva from three donors (lanes 3,4,5 
compared to 1).  
Figure 2.1.6B shows a histogram with average values of quantified signals of Western blot 
bands from six independent experiments. While NadA is induced by 4HPA as well as by 
90% human saliva, MafA expression is co-repressed by both 4HPA and saliva at 50% and 
90% concentrations, in a statistically relevant manner with respect to its basal level in GC 
growth.  
This analysis suggests that the 4HPA molecule used in our experiments mimics a signal 
present in the human saliva, which produces the same regulatory effects on nadA and 
mafA expression.  
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Figure 2.1.6 - Human saliva has the same activity of 4HPA on NadA and MafA expression. 
(A) Western Blot analyses of total protein of mid log cultures of MC58 incubated for 1 hour either with 
4HPA (lane 1) or with increasing amount of human saliva (HS) from 3 different donors (lanes 3, 4 and 5), as 
indicated. The levels of NadA and MafA proteins are shown. (B) Histogram representing the average 
expression levels of NadA (above) and MafA (below). The average values were calculated by quantification 
of Western Blots bands signals of 2 independent experiments with human saliva of each donor (6 
experiments in total). Expression levels of NadA and MafA of cultures grown solely in GC medium were set 
to 1 arbitrary unit. To note that for the quantification, Western Blots bands were normalized for a non-
specific band, indicated with an asterisk in the panel A, in order to avoid non 4HPA- or NadR-dependent 
effects due to possible protein degradation in saliva. One asterisk (*) means p value < 0.05, two asterisks 
(**) p value < 0.01, both versus the growth in GC.  
 
2.1.8 4HPA has differential activity on NadR binding to type I and type II 
promoters in vitro 
It was previously reported that the 4HPA molecule can attenuate the binding of NadR to 
the nadA promoter in vitro [141], supporting the idea that it interacts with the protein 
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and alters its DNA-binding activity. To investigate the role of 4HPA on the in vitro activity 
of NadR in binding to both type I and type II promoters, we performed gelshift analysis in 
the presence of NadR and increasing amounts of 4HPA on a selected panel of target 
promoter regions (Figure 2.1.7A).We demonstrate that for type I (gap-A1, gluD, putA, 
nadR) promoters, 4HPA is able to inhibit the NadR-DNA binding in vitro in a dose-
dependent manner , similarly to what we reported for nadA [141]. However, addition of 
4HPA had no significant effect on binding of NadR at the type II (mafA1 and mafA2) 
promoters. In a parallel and complementary set of experiments we performed gelshift 
analysis on the promoters of nadA and mafA1 with increasing amount of NadR purified 
protein in the presence or absence of 5 mM 4HPA (Figure 2.1.7B-C). While 4HPA has no 
effect on NadR binding activity on the promoter of mafA1 (Figure 2.1.7C), in order to have 
the same amount of DNA-protein complexes on nadA promoter, more NadR is required in 
presence of 4HPA (Figure 2.1.7B), indicating that 4HPA alleviates the binding of NadR on 
nadA. The same results regarding the 4HPA responsive activity of NadR were also 
observed on distinct NadR binding sites of the nadA and mafA promoters, as well as using 
crude extracts from MC58 strain instead of the recombinant purified NadR protein, to 
ensure that any eventual unknown factor required for NadR mediated repression could 
be present (data not shown).            
This analysis demonstrate that 4HPA affects and decreases the NadR DNA-binding affinity 
only to type I promoters that are induced by 4HPA in vivo, while not having any in vitro 
effect on NadR binding activity on type II promoters that are co-repressed in vivo.  
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Figure 2.1.7 - NadR responds differentially to 4HPA on type I and type II promoter regions. 
(A) Gelshift analysis of selected NadR targets in the presence of increasing concentrations of 4HPA. Radio-
actively labeled promoter regions of the indicated genes were incubated with 0 (lane 1) or 36 nM NadR 
(lanes 2-4) and 4HPA was added at final concentration of 1 mM (lanes 3) and 5 mM (lanes 4). (B) In vitro 
NadR response to 4HPA on the promoter region of nadA and (C) mafA1 studied by gelshift. The nadA and 
mafA1 promoter regions where amplified with primers pairs Nad-N1/Nad-B1 and P375-F/P375-652R, 
respectively. 40fmol of end labelled probe were incubated with increasing amount of NadR protein (nM), 
either with or without 5 mM 4HPA, as indicated. Free probes are indicated by asterisks and DNA bound by 
NadR is indicated by arrow heads.  
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2.1.9 The 4HPA mediated co-repression of mafA is not due to repositioning of 
NadR on the promoter 
In order to understand the mechanism by which 4HPA mediates the NadR co-repression 
of the mafA promoter, we evaluate the possibility that the 4HPA binding to NadR could 
cause a conformational change, leading the repressor to bind a different DNA sequence 
than the one previously observed, causing a more efficient repression. Ligand-induced 
repositioning of the DNA binding domain is not new and has been described for the 
MarR-family of transcriptional repressors [255]. 
To asses this possibility we performed DNAse I footprint analyses of NadR on the mafA 
promoter in absence and in presence of 4HPA (Figure 2.1.8). Ligand binding does not alter 
the operator bound by NadR on the promoter of mafA. Moreover, in agreement with 
EMSA analyses, the NadR DNA binding activity on the promoter of mafA is not altered by 
4HPA. 
Taken together with the previous data, this indicates that the differential 4HPA 
responsive activity of NadR on different types of targets is not due to the intrinsic binding 
activity of the protein and that the nature of the binding site at the type II promoters may 
be different to those of the type I promoters and these differences may define the 
regulation to which they will be subjected. 
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Figure 2.1.8 – 4HPA does not alter the positioning of NadR on the promoter of mafA.  
DNase I footprint analyses of NadR on the promoter region of mafA. 40 fmol of the probe were incubated 
with increasing amount of NadR purified protein as indicated and then cleaved with DNase I, either in 
absence (left) or presence (right) of 5 mM 4HPA. Unchanged regions of protection are indicated with 
vertical unbroken lines. The predicted +1, -10 and -35 are indicated.  
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2.1.10 3C scanning mutagenesis reveals extended NadR binding sequence in the 
operator of mafA promoter region 
In order to elucidate intrinsic differences between single NadR operators at the nadA and 
mafA1 promoters and the role of nucleotides on NadR binding activity, we generated 
DNA probes corresponding to the sequences of the high affinity binding sites of the nadA 
(Op I and OpII) and mafA1 promoters, identified by DNase I footprint. For each probe we 
designed a set of mutants, in which three nucleotides were sequentially substituted with 
CCC. To detect the results of the 3C scanning mutagenesis on NadR binding activity, the 
probes were submitted to EMSA analysis (figure 2.1.9A). By identifying the residues 
whose mutations do not alter the binding of NadR, we defined the minimal binding site 
(MBS) required for NadR binding on each operator (figure 2.1.9B). Mutation of nucleotide 
triplets within the MBS results in either reduced (dark grey residues) or absent (black 
residues) NadR binding activity. Interestingly, the definition of MBS clearly shows that the 
operator on the promoter of mafA1 is significantly extended with respect to the high 
affinity binding sites in promoter of nadA.  
These observations suggest a differential mode of NadR binding between the nadA and 
mafA1 operator, which could be partially responsible for the alternative 4HPA responsive 
activity of NadR at the two promoters. 
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Figure 2.1.9 - 3C scanning mutagenesis of nadA and mafA single binding sites. 
(A) DNA probes corresponding to the wild type NadR-protected sequences from DNAI footprints or to 
mutated sequences, in which sequential triplicate nucleotides were substituted with CCC, were submitted 
to gelshift analysis with increasing amount of NadR purified protein (0, 36 and 360 nM, respectively). The 
mutated nucleotides are in italics and underlined in the sequences above each gelshift. The NadR binding 
activity to each probe is reported below each experiment as a percentage of the binding activity shown by 
NadR on the wild type sequence. Black values are associated with mutation causing loss or highly 
compromised NadR binding activity; dark grey values with less affected NadR binding activity; light grey 
values with not affected NadR binding activity. (N.A.= not active in binding). (B) The minimal binding 
sequence (MBS) of each binding site is shown, with nucleotide substitutions essential for binding in black, 
affecting affinity in dark grey and with no effect in NadR binding activity in light grey.  
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2.2 Structural insight into the mechanism of DNA-binding attenuation of 
NadR by the small natural ligand 4HPA 
NadR is a member of the MarR family of transcriptional regulators. A characteristic 
feature of these proteins is their capability to bind and respond to a variety of effector 
molecules [124, 125]. Although the crystal structures of several MarR homologs have 
been solved in their apo- and ligand-bound states, the molecular mechanisms of 
regulation associated with ligand binding is still not known, partly due to the fact that the 
natural ligand is often not known.  
As seen above, 4HPA is a natural ligand of NadR and is a key factor which determines 
NadR activity. The aim of this part of the thesis is to elucidate the mechanism of 
regulation of NadR by the 4-HPA molecule. We focused on NadR activity in response to 
4HPA on nadA, being the gene majorly affected by NadR. We would like to identify the 
4HPA binding pocket of NadR and the key residues involved in this domain.  
 
2.2.1 Characterization of the structural model of NadR.  
A structural model of NadR was generated using the crystal structure of the 
transcriptional regulator PA4135 from Pseudomonas aeruginosa [256] which shares 42% 
sequence identities with NadR (Figure 2.2.1A). According to this model, the NadR dimer 
adopts the typical “triangle” shape of the MarR family with each monomer consisted of 
the secondary structure elements α1-α2-α3-α4-β1-wing-β2-α5-α6 (Figure 2.2.1B). The 
two monomers associate via a dimerization interface created by their N- and C-terminal 
helices (α1, α5 and α6) and each monomer contains a winged helix-turn-helix (w-HTH) 
DNA-binding motif (α3, α4, β1, wing, β2).  
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The quality of the model was assessed by amide hydrogen/deuterium exchange mass 
spectrometry (HDX-MS), as reported by Brier and collegues [8]. The rate at which backbone 
amide hydrogens (NHs) exchange in solution is directly dependent on the dynamics and 
the structure of the protein [257]. Therefore, regions with secondary structures or 
occluded from the deuterated buffer will exchange more slowly than regions without any 
secondary structures and/or fully exposed to the solvent. As shown by data reported in 
[8] the core of the protein, including the dimerization interface, is well protected from 
exchange, to generate the well-packed hydrophobic core of the dimerization domain. In 
contrast, the w-HTH DNA-binding motif was found to be highly accessible, consistent with 
the fact that these regions must remain fully accessible and/or dynamic to interact with 
DNA [132]. Altogether, the HDX data correlate well with the homology-based structural 
model of NadR. 
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Figure 2.2.1 - Homology model and dynamic analysis of NadR. 
(A) Sequence alignment between NadR and transcriptional regulator PA4135 from Pseudomonas 
aeruginosa. NadR shares 42% sequence identity with PA4135. Dark and grey shading indicates the position 
of the conserved and highly similar residues, respectively. The alignment was performed with CLUTALW.  
(B) Ribbon representation of the proposed homodimeric structure of NadR obtained with SWISS-MODEL 
and based on the X-ray structure of PA4135. One subunit is colored in gold and the other in light blue. 
According to this model, each monomer adopts the typical fold of the MarR family members, which consists 
of 6 α-helices and 2-stranded β-sheets. The dimerization interface and the DNA-binding regions are 
indicated. 
 
2.2.2 Localization of the 4HPA binding pocket 
To localize the 4-HPA biding pocket, the exchange behaviors of the apo- and HPA-bound 
forms were monitored and compared by HDX-MS, as reported in [8], resulting in four 
regions, including Met1-Leu14 (N-term α1), Met22-Leu29 (C-term α1), Asn54-Cys61 (α3) and 
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Tyr104-Glu119 (α5), protected from exchange upon 4-HPA binding. To visualize more precisely 
our results, these regions were mapped onto the structural model of the dimer. 
Interestingly, with the exception of α3, the reduction of solvent accessibility was 
clustered at the interface between the dimerization and the w-HTH DNA-binding domains 
(Figure 2.2.2). This interface has already been identified as a common salicylate-binding 
pocket in several MarR homologues including MTH313 [133], ST1710 [132], SlyA [258] 
and TcaR [130]. Although salicylate does not bind NadR, based on these observations, we 
conclude that 4-HPA likely shares the same protein binding region. 
 
 
 
 
Figure 2.2.2 - The 4HPA binding pocket within NadR. 
Ribbon representation of NadR showing the position of the putative 4-HPA binding region identified by 
HDX-MS. Regions with altered deuterium uptake are colored in orange (chain A) and red (chain B). The 4-
HPA-binding pocket is located at the interface between the dimerization and the DNA-binding domains and 
is mainly formed by the α1 N-terminal domain of chain A and the helices α2, α5 and the α1 C-terminal 
domain of chain B (see expanded view).  
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2.2.3 Mutation of key residues in the 4-HPA binding pocket of NadR 
In an attempt to identify the residues of NadR in contact with 4-HPA in the identified 
binding pocket, an in silico docking approach has been used as described by Brier and 
collegues [8]. As a result of this analyses, a predicted network of hydrogen bonds 
coordinating 4-HPA was observed, which mainly involves residues Arg18, Trp39, Arg40, 
Arg43 and Tyr115 (Figure 2.2.3). These residues were selected for mutagenesis to further 
determine their in vivo and in vitro functions in 4-HPA binding. Additional residues (His7, 
Ser9, Asn11 and Phe25) were identified through the in silico docking approach, and were 
also mutagenised to assess whether they play a role in the binding of the small molecule. 
In order to obtain meningococcal strains expressing the NadR mutated forms, the 
previously described MC58-∆1843 nadR null mutant strain [141] was complemented 
either by the wild type NadR protein or by the introduction of the desired alanine 
substituted forms of NadR. Note that we failed to introduce the R43A substitution in 
NadR and, as a consequence, this residue was not further studied. 
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Figure 2.2.3 - Key residues in the 4HPA binding pocket.  
Tridimensional surface model of the structure of the NadR protein, obtained as described in [8]. The binding 
pocket for the 4-HPA molecule is illustrated in the main model and in the magnification showing residues 
putatively involved in 4HPA binding. 
 
2.2.4 In vivo behaviour of selected site directed NadR mutants  
Total lysates from MC58 strains expressing different forms of NadR were subjected to 
Western Blot analyses of NadA expression to assess the ability of each NadR mutant 
protein to repress nadA expression and respond to the 4-HPA inducer. As reported in 
Figure 2.2.4A, NadR R18A and R40A are unable to repress nadA (compare lines 5 & 9 to 
lines 1 & 3) and mimic the behavior of the ∆1843 strain in the presence and absence of 4-
HPA. These results suggest that both substitutions affect the ability of NadR to repress 
the nadA promoter, likely by preventing DNA binding.  
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The protein NadR W39A presents a lower expression level compared to wild type NadR 
(compare line 7 to lines 1 & 3) which indicates that the stability of the protein is 
compromised by the substitution. Possibly as a result, NadR W39A is unable to repress 
nadA expression in vivo and exhibits a behavior similar to that of the ∆1843 strain. 
Interestingly, the addition of 4-HPA increases the expression level of NadR R39A thus 
suggesting that 4-HPA still interacts and stabilizes NadR W39A (compare lines 7 & 8).  
In contrast to R18A, W39A and R40A, the substitution of Tyr115 by Ala does not abrogate 
the in vivo repressive function of the protein. Interestingly, NadR Y115A represses more 
efficiently nadA than NadR WT thus suggesting that NadR Y115A acts as a hyper-repressor 
of NadA expression (compare line 11 to lines 1 & 3). Moreover, the addition of 4-HPA does 
not affect the repressive activity of NadR Y115A (compare line 11 to lines 2 & 4). Taken 
together, these data reveal that the Y115A substitution compromises the response of the 
protein in vivo to the 4-HPA inducer without abrogating its ability to repress nadA.  
In a second round of mutagenesis, we generated a new set of meningococcal strains 
expressing NadR mutated proteins in the additional residues identified by in silico docking 
(His7, Ser9, Asn11 and Phe25). We then test their ability to repress nadA and sense 4HPA in 
vivo (Figure 2.2.4B). Interestingly, three out of the four new mutations (His7, Ser9 and 
Phe25) lead to a phenotype similar to the one presented by the Tyr115, being able to 
hyper-repress nadA expression (lines 5, 7 and 11 compared to 1) and almost unable to 
respond to 4HPA (compare lines 5 & 6, 7 & 8, 11 & 12, respectively). The mutant in Asn11, 
instead, is just slightly affected in its ability to repress nadA and is able to sense 4HPA, 
leading to induction of nadA (compare lines 9 & 10 to 1 & 2, respectively).  
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Altogether, we can conclude that a class of mutation, altering the residues Tyr115 , His7, 
Ser9 and Phe25, leads to hyper-repression of nadA and greatly affects the 4HPA responsive 
activity of NadR, suggesting that this group of residues play a role, in the identified 
binding pocket, in sensing and responding to the ligand. 
 
 
Figure 2.2.4 - In vivo characterization of NadR mutants. 
(A) Western Blot analysis of the expression level of NadA and NadR in wild type MC58, nadR knockout 
MC58 (∆NadR) and complemented ∆NadR strains. Cells recovered from an overnight culture on plates were 
grown in liquid media until mid-log phase (OD600 of 0.5) and then incubated for 1 h in the presence or 
absence of a fixed concentration of 4-HPA. Cells were harvested and 7 µL of total protein extract from each 
culture was subjected to SDS-PAGE and Western Blot analysis using anti-NadA, anti-NadR or anti-fHBP 
antibodies as loading control. (B) The same western blot analyses was performed on a second set of NadR 
mutants in order to identify more residues involved in 4HPA sensing and responding.   
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2.2.5 In vitro characterization of the DNA- and 4-HPA binding activities of the 
purified NadR mutant proteins 
To further elucidate the behavior of the NadR mutants R18A, W39A, R40A and Y115A, the 
recombinant proteins were expressed and purified from E. coli to assess their in vitro 
DNA-binding activity as well as their response to 4-HPA. Further analyses reported in [8] 
demonstrated that the solubility, stability and global fold of NadR Y115A and R40A were 
comparable to that of wild-type NadR, while both R18A and W39A substitutions 
significantly modify the native structural integrity of the protein, precluding their use in in 
vitro analyses.  
To test the binding activity of the NadR proteins in vitro, we prepared a radiolabeled DNA 
probe containing the high affinity binding site OpI from the nadA promoter [141]. The 
binding specificity of NadR WT to the OpI labeled probe was first assessed by EMSA in the 
presence or absence of increasing amounts of either sonicated salmon sperm DNA (non-
specific competitor) or non-labeled OpI DNA (specific competitor). As shown in Figure 
2.2.5A (lines 1-3), a slow migrating complex is formed between NadR WT and the OpI 
labeled probe in the presence of 15 ng protein. The addition of increasing amounts of 
non-specific competitor does not disrupt the complex (Figure 2.2.5A, lines 4-6), while the 
use of cold-OpI DNA prevents the binding of NadR WT to the radiolabeled OpI probe in a 
dose dependent manner (Figure 2.2.5A, lines 7-9). This experiment demonstrates that 
NadR WT binds specifically to the OpI site of the nadA promoter. Similar results were 
obtained using a labeled probe comprising the high affinity binding site OpII [141] from 
the nadA promoter (data not shown).  
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We next investigated the in vitro ability of NadR Y115A and R40A to bind to the OpI 
labeled probe. While NadR WT forms a DNA-protein complex with OpI, no interaction 
could be detected with NadR R40A even at high protein concentrations (Figure 2.2.5B). 
The DNA-binding activity of NadR R40A is abolished by the substitution indicating that 
Arg40 is essential for DNA binding. Therefore, the in vivo defect of this mutant to repress 
NadA can be directly linked to its incapability to interact with the nadA promoter. In 
contrast to NadR R40A, the Y115A substitution does not abrogate the in vitro DNA-
binding activity of the protein (Figure 2.2.5B). Interestingly, NadR Y115A binds OpI with a 
lower affinity compared to NadR WT. The apparent reduction of DNA-binding affinity 
contrasts with the in vivo hyper-repressive activity of NadR Y115A and suggests that the 
repressive ability of the NadR protein is not exclusively based on its ability to bind the 
nadA promoter DNA. Finally, the addition of 4-HPA does not disrupt the NadR Y115A/DNA 
complex even at 10 mM concentration (Figure 2.2.5C). In vitro experiments to assess 
NadR binding activity and 4HPA response were performed also with the OpII labeled 
probe and identical results were obtained (data not shown).  Moreover the same results 
were also confirmed on the whole promoter of nadA, comprising multiple binding sites, 
and using crude extracts instead of the NadR purified protein, to avoid the possibility that 
unknown factors required for NadR activity were missing in the reaction (Figure 2.2.5D). 
Taken together, these data demonstrate that while NadR R40A has lost DNA-binding 
activity and no longer represses nadA, NadR Y115A is a hyper-repressor and is ‘blind’ to 
the 4-HPA molecule.  
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Figure 2.2.5 - Substitution Y115A completely abolishes the in vitro effects of 4-HPA.  
(A) Gel-mobility shift assays performed with a radioactively labeled DNA probe containing the individual OpI 
operator in the presence of increasing amounts of purified NadR WT (lines 1-3) and in the presence of 
either increasing amount of a non-specific competitor (salmon sperm DNA, lines 4-6) or a specific 
competitor (cold OpI DNA, lines 7-9). The positions of the free and complexed DNA are indicated. (B) Gel-
mobility shift assays showing the binding activity of NadR WT, NadR R40A and NadR Y115A on the OpI radio 
labeled probe. The R40A substitution completely abolishes the DNA-binding activity of NadR while the 
Y115A substitution reduces the DNA-binding affinity. (C) Gel-mobility shift assay reporting the effects of 4-
HPA on the OpI binding activity of NadR WT and NadR Y115A. The presence of increasing concentrations of 
4-HPA only induces the release of the DNA probe from NadR WT. (D) Gel-mobility shift assay performed 
with crude extracts (Crude Ex.) on the whole promoter of nadA, comprising multiple binding sites. The 
effects of substitution Y115A on NadR DNA binding and 4HPA responsive activities are reported (5mM 4HPA 
is added were indicated).  
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2.2.6 NadR Y115A does not act as a hyper-repressor on the promoter of mafA1 
To assess if NadR Y115A also had hyperrepressive activity on other NadR target 
promoters, namely type II, we further investigated both the in vivo behavior and the in 
vitro binding activity of the NadR Y115A on the single operator structured mafA1 
promoter.  
Western blot analysis (Figure 2.2.6A) reveals that the MafA1 protein level is not altered in 
vivo by the replacement of NadR wild type with the Y115A. EMSA experiments, 
performed on the whole promoter of mafA1 with crude extracts (Figure 2.2.6B), show 
that NadR Y115A has a reduced binding activity in vitro compared to the wild type 
protein, accordingly with what we saw on the promoter of nadA. However, because the 
binding mode of NadR on type I and type II promoters could be different as demonstrated 
above (Figure 2.1.9), the reduced in vitro binding activity of Y115A results in no 
detectable binding on promoter of mafA1 in vitro, even with high amount of crude 
extracts. As previously demonstrated (Figure 2.1.7), 4HPA has no effect on NadR binding 
activity on the promoter of mafA1 
The fact that the hyper-repressive activity of Y115A is only visible on the type I promoter 
of nadA comprising multiple NadR binding sites, but not on the type II promoter of mafA1 
comprising one single NadR binding site, suggests that this is not an intrinsic property of 
the mutant protein, rather it is linked to the promoter architecture of the gene which is 
acting on and could be partly due to an altered tetramerization/multimerization capacity 
of the mutant.  
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Figure 2.2.6 – In vivo and in vitro characterization of NadR Y115A on mafA1.  
(A) Western blot analysis showing the level of expression of MafA1 in presence or absence of either the 
NadR wild type or the Y115A, as indicated. (B) Gel-mobility shift assay performed with crude extracts (Crude 
Ex.) on the whole promoter of mafA1, comprising only one NadR binding site. The effects of substitution 
Y115A on NadR DNA binding and 4HPA responsive activities are reported (5mM 4HPA is added were 
indicated).  
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2.3 Transcriptional Regulation of the nadA Gene Impacts on the 
Prediction of Coverage of the 4CMenB Vaccine 
NadA is one of the major antigens of the 4CMenB vaccine, therefore the regulation of its 
expression impacts on the vaccine coverage prediction. NadA is repressed by NadR under 
in vitro growth conditions. As seen in previous chapters, different approaches have been 
followed in order to mimic nadA expression during host infection, including the use of 
physiologically relevant molecules and the ex vivo model of saliva, under which NadR-
repression is relieved.  
The aim of this part of the thesis is to investigate whether the level of expression of nadA 
is different between in vitro growth condition and during invasive infection using in vivo 
models. We evaluate further how this difference could implicate on current methods for 
coverage prediction analyses and whether, when taking this into consideration, we could 
better predict the contribution of NadA in vivo to the effectiveness of the 4CMenB 
vaccine.  
 
2.3.1 Strains with MATS RP ≤ PBT express NadA in an immunogenic form during 
invasive disease 
Litt and colleagues [205] observed that many protein antigens, including the NadA 
protein, were recognized by antibodies present in sera of children convalescing after 
meningococcal disease. Importantly, NadA was significantly more strongly recognized by 
convalescent patients infected with strains carrying the nadA gene, than by uninfected 
control subjects [205]. We have extended this study by subjecting the 14 nadA positive 
isolates, matched to the sera of the Litt study, to Western blot and MATS analysis in order 
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to visualize the in vitro levels of NadA expression of the infecting strain. In Figure 2.3.1A, 
Western blots reveal that while the regulator NadR is expressed comparably by all strains 
tested, the levels of NadA are variable, and some strains (Nm067, Nm100 and Nm188) 
failed to express the protein at detectable levels under the in vitro growth condition used. 
When analyzed by MATS, the level of NadA expression, calculated as relative potency 
compared to a reference strain (5/99), correlated well with Western blots results (Figure 
2.3.1B and Table 2.3.1). As shown, only 5 strains have RP values above the PBT of NadA 
which is 0.009 (Nm036, Nm037, Nm081, Nm088 and Nm154), while the remaining strains 
show RP ≤ PBT.  However, sera from children infected either by strains that failed to 
express NadA in vitro (MATS RP = 0) or by strains with a NadA RP < PBT, nonetheless are 
able to recognize at least one form of the NadA recombinant proteins used in the dot blot 
experiments of Litt and colleagues ([205] and Figure 2.3.1C) more efficiently than sera 
from subjects infected by nadA- meningococci. 
These data show that strains with MATS RP values below the PBT are nevertheless able to 
express the NadA protein in an immunogenic form during invasive disease, driving a 
robust humoral response. This observation suggests that the levels of expression of NadA 
under in vitro growth conditions may differ from, and be lower than, those reached 
during infection in the human host.  
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Figure 2.3.1 - Strains with MATS RP ≤ PBT express NadA in an immunogenic form during infection.  
(A) Western blot analyses of the wild type nadA+ strains from the Litt study isolated from convalescing 
children after meningococcal disease [205], showing NadA and NadR expression. The NadA protein migrates 
at the molecular weight of about 98 kDa corresponding to the trimeric form of the protein, but varies 
slightly according to the NadA allele expressed by each strain, while the NadR band migrates at 16 kDa. (B) 
MATS relative potency (RP) of NadA determined by the MATS ELISA for the panel of isolated strains. A black 
dashed line represents the positive bactericidal threshold (PBT) for NadA. The RPs of each strain are 
reported in supplementary table 1. (C) Spot intensity of dot blot experiments adjusted from the study of Litt 
and colleagues [205]. Reactivities of sera from children infected with the reported isolated strains towards 
the full length NadA recombinant protein (961) as well as two truncated forms comprising the extracellular 
portion of NadA (961cm and 961c2) are reported. The average values of reactivity for the 14 nadA+ strain 
and the 17 nadA- strains from the original study were calculated and reported in the graph as references 
(Avrg NadA+ and Avrg NadA-, respectively). 
 
 
Table 2.3.1 - MATS RPs of NadA for nadA+ strains isolated from patients 
 MATS NadA 
Strain Low CLa RPb High CLc 
NM036 0.131 0.151 0.174 
NM037 0.027 0.035 0.045 
NM066 0.003 0.005 0.007 
NM067 NA NA NA 
NM069 0.003 0.004 0.005 
NM081 0.173 0.214 0.256 
NM088 0.245 0.342 0.501 
NM100 NA NA NA 
NM119 0.003 0.004 0.004 
NM145 0.008 0.009 0.013 
NM154 0.105 0.14 0.186 
NM156 0.002 0.002 0.003 
NM188 NA NA NA 
NM191 0.002 0.003 0.004 
 
a = experimental low confidence limit (StatLIA). 
b = relative potency.  
c = experimental high confidence limit (StatLIA). 
NA = not available. 
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2.3.2 All strains carrying the nadA gene can express high levels of the NadA 
protein and therefore be killed by vaccine-induced bactericidal antibodies 
The main mediator of varying expression levels of NadA within and between strains is the 
transcriptional regulator NadR, through its ability to differentially repress the phase 
variant promoter of nadA. To understand the relevance of NadR repression to the 
variable expression levels of NadA observed in different MenB strains under in vitro 
conditions, a representative panel of strains covering a range of NadA expression levels 
was selected (Table 2.3.2) and the nadR gene was deleted in each of them. We evaluated 
the implications of the alleviation of NadR repression under in vitro conditions by 
Western blot, MATS and SBA analysis (Figure 2.3.2 and Tables 2.3.3 and 2.3.4). 
As previously shown [141], all the nadR- strains expressed considerably more NadA than 
their wild type forebears, confirming that deletion of nadR results in strong induction of 
NadA. Furthermore, all nadR- strains expressed comparable high levels of the NadA 
antigen measured by Western blot (Fig. 2.3.2A). The MATS assay performed on wild type 
and nadR- strain pairs demonstrated that the ratio of the RP values for NadA increased 
from 3 to up to 100-fold in the mutant strains (Fig. 2.3.2B), indicating that all these strains 
can express high levels of immunogenically relevant NadA antigen when NadR repression 
is abolished. The MATS assay correlates with the hSBA [243] at values of RP higher than 
the PBT. Therefore, we compared the ability of immune sera to kill the nadR- knock out 
strains and their related wild types. Table 2.3.3 shows that sera from mice immunized 
with NadA alone or with the 4CMenB vaccine have an increased NadA-specific 
bactericidal activity on nadR- strains compared with wild type strains. The only exception 
is for strain 5/99, in which, as expected, there is no significant difference in SBA titres 
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between the wild type and the nadR- strains. In this strain the NadR-mediated repression 
of NadA is minimal: NadA is highly expressed in the wild type strain. Sera from 
immunizations with NHBA and fHbp (Table 2.3.3) had invariant activity towards wild-type 
and nadR- strains, confirming that the knock-out of nadR does not alter the susceptibility 
of these strains in the bactericidal assay and suggesting that neither NHBA nor fHbp 
expression is regulated in a NadR-dependent way. hSBA assay performed on the mutant 
strains demonstrates that sera from clinical trial subjects of different age groups 
immunized with the 4CMenB vaccine formulations were efficiently able to kill all nadR- 
strains and exhibited extremely high bactericidal titers (Table 2.3.4). Of note, antibodies 
present in sera from some age groups and apparently ineffective in killing of certain 
strains (e.g. B3937 and NGP165) show the ability to efficiently kill the equivalent 
recombinant strains once NadR repression has been relieved.  
Taken together these data demonstrate that all the strains carrying nadA can potentially 
express NadA to a level which is sufficient to be recognized and to mediate killing by 
bactericidal antibody elicited by the 4CMenB vaccine. 
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Table 2.3.2 - Selected strains used in this analysis 
Strain Clonal complex STa Year Countryb Typing 
PorA Match 
OMV_NZc 
fHbp IDd NHBA NadA  variant 
5/99 ST-8 complex/Cluster A4 1349 1999 N B:2b:P1.5,2 N 23 20 2 
961-5945 ST-8 complex/Cluster A4 153 1996 AUS B:2b:P1.21,16 N 16 20 2 
LNP17094 ST-8 complex/Cluster A4 153 1999 F B:2b:P1.10 N 16 22 2 
B3937 ST-18 complex 6344 1995 D B:22:P1.16 N 17 23 3 
M10574 ST-32 complex/ET5 complex 803 2003 USA B:NT:P1.7-2,13-1 N 76 3 1 
M14933 ST-32 complex/ET5 complex 32 2006 USA B:ND:P1.22-1,14 N 76 3 1 
MC58 ST-32 complex/ET5 complex 74 1985 UK B:15:P1-7,16b N 1 3 1 
NGP165 ST11 complex/ET-37 complex 11 1974 N B:NT:P1.2 N 29 29 2 
 
a = multilocus sequence type. 
b = AUS, Austria; D, Denmark; F, France; N, Norway; UK, United Kingdom; USA, United States of America. 
c = No strains match the PorA P1.4 allele in the OMV_NZ vaccine component. 
d = The fHbp allele identification numbers (ID) are reported here according to Oxford database nomenclature. 
2     RESULTS   
 
 
 
90 
 
 
Figure 2.3.2 - NadA espression levels in a panel of wild type and nadR knock out strains.  
(A) Western blot analyses of wild type and relative nadR knocked out strains. The NadA and NadR levels of 
expression are shown for the representative panel of strains selected and the mutant isogenic strains 
lacking the nadR gene. Different levels of expression of NadA between wild type strains are associated with 
different phase variants of the nadA promoter repressed with different efficiency by the regulator NadR, as 
previously described [141]. (B) Ratio of MATS RPs of nadR knocked out strains versus the wild type strains 
for the NadA antigen. The RP of wild type strains and the fold increase of NadA RP of nadR- strain, 
calculated by dividing the RP value of nadR- strains by the RP value of the relative wild type strains, are 
reported in the graph.  
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Table 2.3.3 - rSBA performed with immunized mice sera and rabbit complement on wild 
type and nadR knock out strains   
Strain NHBA fHbp NadA 4CMenBa 
5/99 512 <16 >65536 >32768 
5/99 nadR- 128 <16 >65536 >65536 
961-5945 1024 1024 1024 4096 
961-5945 nadR- 1024 2048 >65536 >65536 
LNP17094 1024 <16 128 4096 
LNP17094 nadR- 512 <16 32768 >65536 
B3937 <16 1024 512 2048 
B3937 nadR- <16 512 >65536 >65536 
M10574 4096 128 >8192 >8192 
M10574 nadR- 4096 64 >32768 >32768 
M14933 4096 <16 512 >8192 
M14933 nadR- 4096 <16 >32768 >32768 
NGP165 128 <16 128 512 
NGP165 nadR- 128 <16 >32768 >32768 
 
a = vaccine formulation with both the three recombinant major antigen and the OMVs, as described in the 
text. 
Grey boxes associate with no killing in the rSBA.  
Light green boxes associate with killing in the rSBA.  
Dark green boxes associate with significant increased killing in the rSBA, due to NadR knocking out 
(significant increament = at least 2 dilution titers). 
Strains were considered killed if pooled mouse sera achieved an rSBA titer ≥128.  
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Table 2.3.4 - hSBA on wild type and nadR knock out mutants selected strains  
Strain 
study1 study2 
Adult Infant 
pre-immune 4CMenB post 3a Routine 4CMenB post 4b 
5/99 <4 256 <4 >512 
961-5945 <4 16 <2 16 
961-5945 nadR- <4 >512 <4 >512 
LNP17094 <4 16 <2 16 
LNP17094 nadR- <4 >512 <4 >512 
B3937 <4 8 <2 <2 
B3937 nadR- <4 >512 8 >512 
M10574 <4 32 <2 64 
M10574 nadR- <4 >512 <4 >512 
M14933 <4 16 <2 32 
M14933 nadR- <4 >512 8 >512 
NGP165 <4 <4 2 4 
NGP165 nadR- <4 >256 4 >256 
 
a = 3 doses of the vaccine given at 0, 2 and 6 months. 
b = 3 doses of the vaccine given at 0, 2 and 6 months + 1 boost between 12 and 24 months. 
Grey boxes associate with no killing in the hSBA.  
Light green boxes associate with killing in the hSBA.  
Dark green boxes associate with significant increased killing in the rSBA, due to NadR knocking out 
(significant increament = at least 2 dilution titers). 
Strains were considered killed if pooled sera from different age groups who received the 4CMenB achieved 
an SBA titer ≥8. 
 
2.3.3 NadA expression can be induced in vitro by different physiologically relevant 
signals  
It has been previously shown that NadR-mediated repression of the nadA promoter can 
be alleviated by 4-HPA, a catabolite of aromatic amino acids which is commonly found in 
human saliva [141, 147]. As seen above, human saliva has been shown to induce NadA 
expression to the same level as 4-HPA in strain MC58, suggesting that in vivo the nadA 
gene might be induced by signals present in saliva [259-261].  
We used the substrate binding pocket, involved in the interaction of the 4-HPA ligand and 
the NadR repressor, represented in Figure 2.2.2, for in silico docking experiments to 
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screen a number of molecules structurally similar to 4-HPA, in order to identify 
candidates for other potentially physiologically relevant inducers of NadA expression. Any 
molecule that was identified in silico as able to dock in the binding pocket of NadR was 
tested for its ability to induce NadA expression in MC58 in in vitro grown cultures (Figure 
2.3.3A). Among the molecular species tested, some (2-HPA, 2,4-HPA and the 3,4-HPA) 
were unable to induce NadA expression,  while others (3Cl4-HPA, NO2-4-HPA, 3Br4-HPA 
and, to a lesser extent, 3-HPA) increased the level of expression of NadA to a comparable 
level to 4-HPA itself. We then verified which of the newly found inducers might have a 
significant role during meningococcal infection. Interestingly, 3Cl4-HPA, which is 
structurally similar to 4-HPA (Figure 2.3.4A), has been shown to be produced during 
inflammatory processes as a catabolite of chlorinated aromatic amino acids [262], while 
under acid condition or in the presence of polymorphonuclear leukocytes (inflammation), 
the 4-HPA is nitrated to 4-hydroxy-3-nitrophenylacetic acid (NO2-4-HPA) [262]. Therefore 
these molecules represent possible natural ligands that the meningococcus might 
encounter during infection of the host. 
We also assess the hypothesis that meningococcus itself can produce a signal which is 
able to induce nadA expression. In order to do this we recovered the medium of an in 
vitro growth (spent medium) and use it to try to induce nadA in MC58 strain. Figure 
2.3.3B shows that the spent medium is able to induce the expression of the NadA, even if 
to a lesser extent than 5mM 4HPA. This could be probably due to the higher dilution of 
the signal molecule in the spent medium.  
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Altogether, these results suggest that during infection, multiple signal molecules, either 
produced by the host (4HPA, 3Cl4-HPA, NO2-4-HPA or an unknown molecule in saliva) or 
by meningococci themselves, could lead to the induction of nadA.    
 
 
 
2.3.3 – Identification of novel nadA inducers.  
 (A) Western blot analyses of the level of expression of NadA in the MC58 strain growth in absence or 
presence of small molecules. Mid-log cultures of MC58 were incubated for one hour with 2 or 5 mM of the 
indicated small molecules in order to check in vivo the NadA inducing activity of the compounds. (B) 
Western blot analyses of nadA expression in the MC58 strain following incubation with 30% spent medium 
recovered after 5 or 7 hours liquid cultures. In both experiments the NadR as well as the fHbp levels of 
expression are also reported. The fHbp is used as a gel loading control and indicated with an asterisk in the 
figure. To note that none of the small molecules have an evident effect on either the NadR or the fHbp 
expression levels. 
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2.3.4 NadA induction in the selected strain NGP165 
The 4CMenB vaccine has been formulated in order to confer protection by targeting 
multiple antigens on the surface of as many strains as possible. To evaluate the 
contribution of NadA to vaccine coverage and to test the hypothesis that levels of NadA 
expression in vitro could underestimate the predicted efficacy of bactericidal antibody in 
mediating the killing of NadA positive strains during infection, we selected strain NGP165 
for a case study. NGP165 is mismatched to 4CMenB for fHbp and PorA (carrying fHbp 
variant 3.29 and PorA serosubtype 1.2, while the vaccine comprises fHbp variant 1.1 and 
PorA serosubtype 1.4), and with respect to NHBA, it has MATS RP below the PBT and 
almost negative rSBA titers in the preclinical studies (Table 2.3.3). Thus only the NadA 
antigen could plausibly contribute to 4CMenB-induced antibody-mediated killing of this 
strain.    
Due to their physiological relevance we decided to test both the 4-HPA and the 3Cl4-HPA 
molecules in in vitro assays using NGP165 selected strain, in order to assess the putative 
level of NadA expression in the host.   
Figure 2.3.4B shows NadA expression is induced by both 4-HPA and 3Cl4-HPA to a similar 
level, with no statistically significant difference seen between the inductions achieved by 
the two molecular species in three biological replicates. As previously reported for strain 
MC58 [259-261], human saliva from different donors is able to induce NadA expression in 
a dose-dependent manner, to the same extent as 4-HPA (or 3Cl4-HPA, data not shown) in 
NGP165 (Figure 2.3.4C).  
The use of HPA derivatives in in vitro assays achieves levels of NadA expression similar to 
ex vivo human saliva and may mimic the predicted levels in the host.   
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Figure 2.3.4 - Induction of NadA by different physiologically relevant signals in the NGP165 selected 
strain.  
(A) Representation of the chemical structure of the 4-HPA and the 3Cl4-HPA compounds. (B) Western blot 
analyses of the level of expression of NadA in the NGP165 strain. The wild type NGP165 strain was grown 
for about two hours to reach mig-log phase of growth and then incubated with either the 4-HPA or the 
3Cl4-HPA molecule for one hour to assess the induction of the NadA expression compared to the basal level 
of the in vitro growth in GC alone. The experiment was repeated with three biological replicates and the 
Western blot bands were quantified using a loading control as reference (fHbp). One representative 
Western blot is reported together with the histogram summarizing the results of the three replicates. A 
one-way non parametric ANOVA followed by a Bonferroni post test were performed to evaluate the 
statistical significance of results. The levels of NadA expression are significantly higher in the presence of 
the 4-HPA and the 3Cl4-HPA molecules with respect to the basal level in GC (**= pval < 0.01), but not 
statistically different between them (ns = not significant). (C) Induction of the NadA expression in the 
NGP165 strain with human saliva (HS). On the left, Western blot analyses of total protein of mid-log 
cultures of NGP165 incubated for 1 hour with either 4-HPA (lane 2) or with increasing amount of human 
saliva from 3 different donors (lanes 3, 4 and 5), diluted (V/V) as indicated. The levels of expression of NadA 
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are shown. On the right, histogram reporting the average values of NadA expression from 5 independent 
experiments, after quantification of the band signals. Western blot bands were normalized for a non-
specific band, indicated as loading control on the right panel, in order to avoid non 4-HPA- or NadR-
dependent effects on NadA expression due to possible protein degradation in saliva. A one-way non 
parametric ANOVA followed by a Bonferroni post test were performed. * = pval < 0.05, ** = pval < 0.01 in 
the graph, comparing all condition to the basal GC medium level. Comparable level of NadA induction to 4-
HPA and saliva were obtained with the 3Cl4-HPA molecule (data not show).  
 
2.3.5 In NGP165, neither 4HPA nor 3Cl-4HPA have any effect on the expression of 
the other major antigens of the 4CMenB 
In order to be sure that the effects that we could see in NGP165 following nadA induction 
with either 4HPA or 3Cl-4HPA would be only due to the increase of the amount of NadA, 
we assess the effect of these molecules on NHBA and fHbp, the other two major antigens 
in the 4CMenB vaccine. According to the regulon of NadR that we identified, these two 
molecules are not regulated by this repressor. However a NadR-independent, HPA-
dependent effect on their expression cannot be excluded.  
Figure 2.3.5 demonstrates that the HPA molecules do not alter the expression of either 
NHBA or fHbp.  
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Figure 2.3.5 – Expression of NHBA and fHbp in NGP165 in response to nadA inducers 
(A) Representative Western blot analyses of the level of expression of NHBA and fHbp in the NGP165 strain, 
in response to 4HPA and 3Cl-4HPA, as indicated. The constitutively expressed RNA chaperon Hfq has been 
used as a loading control. The experiment was repeated three times with independent biological replicas. 
(B) Histogram reporting the average values of NHBA and fHbp expression from 3 independent experiments, 
after quantification of the band signals. Western blot bands were normalized on Hfq. Standard deviations 
are reported. A one-way non parametric ANOVA followed by a Bonferroni post test were performed, but no 
statistically relevant differences were seen neither for NHBA nor fHbp in different conditions.  
 
2.3.6 hSBA and MATS performed with 3Cl4-HPA predict 4CMenB vaccine coverage 
of the NGP165 strain 
We performed the hSBA and the MATS assays on the NGP165 wild type and the nadR 
knock out mutant grown in the absence or presence of 3Cl4-HPA (Table 2.3.5). The 
NGP165 wild type strain, expressing low levels of NadA in vitro (Figure 2.3.4B), has a NadA 
MATS RP = 0.005, below the PBT for NadA (0.009). Results of the hSBA demonstrated that 
NGP165 was resistant to killing by pooled sera from infants who received 4 doses of 
4CMenB. When grown in the presence of 3Cl4-HPA, the MATS RP of NGP165 increased to 
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0.028 (Table 2.3.5) and the strain was rendered susceptible in the hSBA using the same 
infants’ sera. Bactericidal titers increased from 4 with pre-immune sera to 128 with 
immunized sera (Table 2.3.5). As seen for other strains tested, a more pronounced 
increase in NadA expression was seen in the nadR- mutant, in which the nadA gene is fully 
de-repressed (NadA MATS RP = 0.503). This situation correlates with positive bactericidal 
titers of >256 in hSBA.  
In conclusion, using a modified in vitro growth protocol (with HPA supplementation) that 
we consider more accurately reflects the level of NadA expression that occurs in vivo, the 
MATS and hSBA assays predicted that NGP165 would be efficiently killed during infection 
by anti-NadA antibodies in sera of subjects immunized with the 4CMenB vaccine. 
 
Table 2.3.5 - hSBA and MATS of the NGP165 strain performed with the 3Cl4-HPA 
molecule 
Strain Inducer NadA MATS RP 
hSBA 
study3 
Infant 
routine 4CMenB post 4 
NGP165 none 0.005 2 4 
NGP165 3Cl4-HPA 0.028 4 128 
NGP165 nadR- none 0.503 2 >256 
 
Grey boxes associate with either MATS RP below the PBT (which is 0.009 for NadA) or no killing in the hSBA. 
Green boxes associate with either MATS RP above the PBT or killing in the hSBA.  
Strains were considered killed if pooled sera from infants who received three immunizations plus one 
booster of 4CMenB achieved an SBA titer ≥8.  
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2.3.7 Sera from 4CMenB-immunized infants protect infant rats from infection with 
strain NGP165. 
To determine whether NGP165 would be killed in vivo by anti-NadA antibodies, we 
performed a passive protection assay in the infant rat model [263]. Figure 2.3.6 reports 
the results of these experiments. Groups of infant rats were inoculated i.p. with an 
infectious dose (105 CFU) of NGP165 after being treated with control serum, or pre- or 
post-immune sera from mice and infants immunized with either NadA or the 4CMenB. 
Administration of pre-immune sera from either mice or human infants had no effect on 
the ability of NGP165 to infect infant rats: 105 CFU of NGP165 led to sustained infection in 
all but one of the 19 animals tested. Sera from mice or human infants immunized with the 
4CMenB vaccine formulation conferred protection on the infant rats as well (15 out of 16 
and 4 out of 4 rats respectively protected in two experiments). The same human sera 
results in protection of infant rats from infection with a NGP165 NHBA KO strain (4 out of 
5 rats), demonstrating that killing of the strain is not due to anti-NHBA antibodies present 
in the sera. Taken together these data suggest that in this in vivo model NadA is 
expressed to a sufficient level to be recognized by specific anti-NadA antibodies elicited 
by NadA in the 4CMenB vaccine and to mediate killing of the bacterium.  
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Figure 2.3.6 - Passive protection in the in vivo rat model.  
(A) Plot of the number of CFUs counted for each infant rat, alternatively injected with either mice 
preimmune sera or mice immunized sera, as indicated below the chart. (B) Plot of the number of CFUs 
counted for each infant rat, alternatively injected with either pre-immune human sera or sera from human 
immunized with the 4CMenB vaccine, as indicated. Infant rats were infected with either NGP165 wild type 
or NGP165 NHBA KO Circles indicate single infant rats, while solid horizontal black lines indicate the average 
of CFUs counted for each condition, error bars are also reported. A horizontal dashed line indicates the limit 
of quantification of the CFUs. (* = p val < 0.05, ** = p val < 0.01, comparing all conditions to rats injected 
with pre-immune sera). No statistical difference is present between the protection of infant rats from 
infection of either NGP165 wild type or NHBA KO strains. (C) Table showing the results obtained in the in 
vivo passive protection model. 
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2.3.8 The promoter of nadA is activated in vivo during infection of the infant rat model 
In order to directly evaluate the expression/induction of nadA during infection, we 
generated reporter strains carrying the promoterless luciferase operon (negative control) 
or carrying the operon under the control of the nadA promoter (PnadA-lux). The 
bioluminescence of the resulting strains was evaluated in in vitro experiments. 
Interestingly, the PnadA-lux strain is significantly less bioluminescent than the negative 
control (data not shown), indicating that the nadA promoter is efficiently repressed under 
in vitro conditions and as expected 4HPA-specific induction of PnadA-lux (10-fold) and the 
derepression of PnadA-lux in the NadR KO background (385-fold) was observed (Figure 
2.3.7A). The infective dose of 104 CFU of the negative control and the PnadA-lux reporter 
strains were used to infect groups of 5 infant rats and images of ventral views of 
intraperitoneally infected rats were collected either immediately or 3 and 24 hours after 
infection. Immediately after infection, both the negative control and the PnadA reporter 
strains are poorly bioluminescent (less than 1.5-fold change from the background) (dark 
grey and white circles, respectively in Figure 2.3.7B), however three hours post infection, 
the PnadA-lux reporter strain is significantly induced (6-fold on average) while the 
negative control maintains low levels of bioluminescence (Figure 2.3.7B-C). It is worth 
noting that in Pnad-luxA infected rats a widespread bioluminescence is observed over the 
entire rat indicative of bioluminescence from bacteria in a systemic infection. 24 hours 
after infection the bioluminescent signals from both the negative control and the reporter 
strains are almost indistinguishable from the background (Figure 2.3.7B). These data 
produced in the infant rat model of septicemia, indicate that the nadA promoter is 
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induced during infection in vivo, suggesting that NadA is expressed during invasive 
disease.  
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Figure 2.3.7 - Direct visualization of PnadA expression in the in vivo infant rat model.   
(A) Images of serial dilution of liquid cultures of wild type and relative NadR KO strains carrying either the 
promoterless lux operon (negative control) or the PnadA-lux reporter, grown in absence or presence of 
4HPA, were taken with an IVIS 100 system. Bioluminescence values were obtained after analyzing the 
images with the Living Image 3.1 software. The basal level of bioluminescence of these strains was obtained 
by setting to one the bioluminescence of wild type strains observed during growth in GC medium solely. 
The bioluminescence increment from this basal level was calculated for relative NadR KO strains and during 
growth in GC in presence of 4HPA and reported in the graph, as indicated (white columns represent the 
negative control and black columns represent the PnadA-lux reporter). (B) Histogram representing the 
bioluminescence increment from the background (infant rats infected with the 2996 wild type strain) of 
groups of 5 infant rats infected with 104 CFU of the 2996 strain carrying an integrated copy of either the 
promoterless luxCDABE operon (negative control, dark grey circles) or the 2996 nadA-lux reporter strain 
(white circles) as well as median values of bioluminescence increment of each group (solid horizontal red 
lines) at time points indicated. T-test analyses were performed to assess statistical significant differences 
between the two groups of infant rats at each time point (* = pval <0.05, *** = pval <0.001, ns = not 
significant). (C) Panel of ventral views of groups of 5 infant rats infected with 104 CFU of the negative 
control or the PnadA-lux reporter, as indicated, taken 3 hours after infection. Red boxes indicate the regions 
of interest (ROI) that were taken into consideration by the Live Imaging software to quantify bioluminescent 
values. Blood samples were recovered 24 hours after infection and CFU counts confirm that the bacterial 
load within infant rats infected with different strains was similar.  
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3 DISCUSSION 
3.1 In the NadR regulon, adhesins and diverse meningococcal functions 
are regulated in response to signals in human saliva 
In this first part of the thesis we dissect the role of NadR, a member of the MarR family of 
transcriptional regulators, in N. meningitidis and define its regulon. We show that NadR 
co-ordinately regulates many genes that all respond to the small signalling molecule 
4HPA, a metabolite of amino acid catabolism that is secreted in human saliva. Of the 
genes with an altered expression profile, NadR had the greatest effect on the nadA gene 
which exhibited >60 fold derepression in the NadR mutant. All other genes in the NadR 
regulon display much lower expression rate changes, in accordance with the previously 
described NadR targets [90].  
Interestingly in addition to the NadA adhesin, NadR represses 2 mafA (multiple adhesin 
family A) loci of MC58 (NMB0375 and NMB0652), encoding putative adhesins. We have 
demonstrated that NadR controls the expression of NadA and the MafA1/A2 adhesins in 
opposing ways in response to the 4HPA inducer molecule. While 4HPA induces NadA 
expression, it results in co-repression of the MafA1 and MafA2 adhesins in a panel of 
meningococcal strains. Interestingly, human saliva has the same differential effect as 
4HPA on NadA and MafA expression, suggesting that in vitro 4HPA could mimic 
physiologically relevant signaling molecules in vivo. The presence of differential 
regulatory responses mediated by one unique regulatory protein suggests that the roles 
of the NadA and MafA adhesins are mutually exclusive. This regulatory response may 
indicate an important molecular switch enabling adaptation of meningococcus to 
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changing niches: as a consequence of the external changing niche-specific signals, a 
dedicated group of adhesins (i.e. NadA or MafA) relevant for the colonization of that 
niche will be expressed.  
Moreover, the NadR-repressed glycolytic enzyme encoded by the gapA-1 gene was 
recently shown to play a role in adhesion in meniningococcus [264] and its homologues in 
many other systems are well known to function as a surface exposed adhesin [265-270]. 
Therefore, Gap-A1 may represent a third adhesin under the control of NadR that will be 
co-expressed with NadA in response to niche signals.  
We have demonstrated that the nadA and other 4HPA-induced promoters (type I) 
comprise multiple NadR binding sites while the mafA1/A2 promoters (Class II) consist of 
only one binding site for NadR, centred downstream of the promoter sequence. In 
addition, 4HPA alters the DNA binding activity of NadR at only type I promoters in vitro, 
without affecting the NadR binding at type II. Therefore, both the architecture of the 
promoter and the nature of the NadR operators at the promoter may direct the response 
that NadR will effect to the same signal.  
We propose a model (Figure 3.1.1) in which the apo-NadR can bind to and repress nadA 
and other 4HPA-induced genes (type I) through a looping mechanism, which may result in 
steric hindrance of RNA polymerase access to the promoter, possibly through dimer-
dimer interactions on multiple binding sites. This model has been previously proposed for 
both the gonococcal farAB promoter [138] and the meningococcal nadA promoter [141] 
and is supported by the binding at these promoters of the Integration Host Factor (IHF), a 
histone-like protein which was demonstrated to bend DNA upon binding [271] and could 
facilitate the interaction between NadR dimers bound at different operators. Following 
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the binding of 4HPA or other biologically relevant signals (Figure 3.1.1, lower panel), the 
NadR protein can be stabilized in a conformational state which is not able to efficiently 
bind to type I operators, thus causing the induction of type I genes. 
On the other hand the mafA1 promoter (type II) could be less efficiently repressed by the 
apo-NadR. However, the 4HPA bound-NadR can still bind at type II binding sites resulting 
in a more effective repression of type II genes in vivo. The interaction of a small molecule 
with a MarR regulator is normally associated with disruption of DNA binding, however 
ligand-binding can enhances the DNA binding activity of MarR homologues [129]. In the 
case of NadR on type II promoters, the 4HPA molecule does not directly increase the 
affinity of the protein for its binding site (figure 2.1.7C). Therefore, we suggest that the 
4HPA mediated co-repression of type II genes is the result of either a less efficient 
promoter clearance due to occupancy of 4HPA bound-NadR at the type II operator or 
different binding kinetics at type II operators between the apo- and the 4HPA bound-
NadR forms.  
All these considerations suggest that, rather than different signals, it seems to be the 
different nature of operators and promoters to decide the kind or regulation performed 
by the NadR protein on its different targets.  
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Figure 3.1.1 - Model of NadR regulation on type I and type II gene promoters. 
The promoters of nadA and mafA1 are schematically illustrated and represent the type I and type II 
promoters, respectively. The top panels show the different NadR mediated repression of its different 
targets. The lower panels show the activity of 4HPA on NadR binding at type I versus type II promoters.  
 
In addition to regulating adhesins, NadR also co-ordinates many other cellular functions in 
response to 4HPA or similar signals present in saliva, controlling a generalized adaptation 
of the meningococcus to the host niche colonization. Interestingly, it has been 
demonstrated that maltodextrins produced in human saliva by α-amylase are crucial for 
group A streptococcus to successfully infect the oropharynx [272, 273], suggesting that 
signals present in saliva, other than 4HPA, could be used by bacteria to modulate the 
gene expression and adapt to the host niche.  
NadR is able to repress the expression of various genes implicated in transport of a range 
of known and unknown substrates, suggesting that it is involved in controlling the 
substrate-uptake machinery of meningococcus during infection. In addition it also 
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regulates genes involved in energy metabolic pathways, supporting the idea that it can re-
route the metabolism of the cell in response to niche signals. In particular, the ability of 
NadR of inducing the pathways for amino acid catabolism, such as proline and glutamate 
utilization, in response to the presence of 4HPA, which is itself an amino acid metabolite, 
suggests that the environmental availability of amino acid metabolites signals to the cell 
that amino acids may be abundantly available and NadR adapts the cell metabolism, 
accordingly. Furthermore, NadR links into other regulatory circuits within the cell by 
affecting expression levels of transcriptional or post-transcriptional regulators, thus 
indirectly regulating other targets. 
In identifying the NadR regulon and the signals to which it responds we have gained 
insights into a co-ordinated response of the meningococcus which may be relevant during 
colonization of the oropharynx. While NadR in meningococcus has evolved away from 
regulating fatty acid resistance, it coordinates a number of seemingly unrelated functions 
within the cell in response to a niche-specific small molecule signal. It is tempting to 
speculate that during colonization of the oropharynx, NadR controls the adhesion 
properties of the cell, while also adapting metabolism and other physiologically relevant 
processes to the competitive host niche.   
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3.2 Structural insight into the mechanism of DNA-binding attenuation of 
NadR by the small natural ligand 4HPA 
After elucidating the global role of NadR, in the second part of the thesis we explored the 
mechanism by which the 4HPA molecule regulates the NadR DNA-binding activity, on 
nadA, on which, as stated above, NadR had the greatest effect among its target genes. 
We found that the 4-HPA ligand binds in a pocket located at the junction between the 
dimerization interface and the DNA-binding lobe. This ligand binding site is mainly formed 
by structural elements of the two monomers including helix α1 of the first subunit and 
helices α1 and α5 of the second subunit. Although the number of salicylate sites on MarR 
molecules is still controversial, superimposition of the NadR/4-HPA complex with 
available representative MarR/salicylate structures shows that 4-HPA shares a salicylate 
binding region common to all available models [130-132]. The position of the ligand 
binding pocket appears therefore well conserved among MarR family members. However 
the ligand binding site of NadR displays significant variations in amino-acid composition 
compared to other representative MarR homologues, which suggests differences in ligand 
specificity. Indeed, NadR does not respond to the broad specific effector salicylate in vitro 
[141] and is unable to associate with the ligand even at high concentrations (our 
unpublished results). These observations suggest that members of this family have 
probably evolved separately to respond to distinct signaling molecules thus enabling 
bacteria to adapt and respond to changing environmental conditions within their natural 
niches.  
The presence of this conserved ligand binding pocket has led to the hypothesis of a 
shared mechanism of regulation among members of the MarR family. For proteins that 
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appear to be preconfigured for DNA binding in their apo configuration, the binding of 
ligands produces a large conformational change that is transmitted to the DNA binding 
lobes [133]. The distance between the two recognition helices that is essential for 
association with two consecutive DNA major grooves is altered in the complex thus 
precluding DNA binding.   
The formation of the 4-HPA/NadR complex results in an overall accessibility of the protein 
similar to the one observed in the absence of the ligand, indicating that 4-HPA likely locks 
NadR in a conformation incompatible with DNA binding without inducing large 
conformational changes in the DNA-binding lobes. The binding of 4-HPA induces minor 
conformational changes in the DNA-binding lobes. This is supported by our mutagenesis 
experiments, in which the substitution of Tyr115 in the ligand binding site alters the 
dynamics of helix α3 (as reported in [8]) suggesting a cross-talk between elements of the 
HPA- and the DNA-binding domains. Moreover, the presence of the ligand seems to be 
not only transmitted to the DNA-binding domain but also to the dimerization interface. 
Indeed, in the Y115A NadR mutant, 4-HPA accelerates the dimer dissociation rate (data 
not shown). It is well established that members of the MarR family possess an intrinsic 
conformational flexibility at the dimerization interface that is exploited on binding of 
either cognate DNA or ligand to modify the position of the DNA-binding domains [124, 
125]. Based on these observations, it is tempting to speculate that 4-HPA makes use of 
the structural malleability of the dimerization interface to alter the position of the DNA-
binding lobes. It seems plausible that 4-HPA reduces the flexibility of the dimerization 
interface to prevent the motions of the DNA-binding lobes required for interaction with 
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DNA. On the basis of this model, the binding of the ligand may lock the DNA-binding lobes 
in place without affecting their global solvent accessibility. 
Finally, our mutagenesis data reveal that a class of mutation represented by Tyr115 
(including His7, Ser9 and Phe25 mutants) plays a key role in the mechanism of regulation of 
NadR by 4-HPA. 4HPA can still bind to NadR Y115A, as reported in [8], suggesting that the 
substitution of this single residue is not sufficient to destroy the ligand binding pocket. 
However, the Y115A substitution compromises the 4-HPA-mediated stabilization of the 
complex and prevents DNA dissociation. Taken together, these data suggest that 4-HPA 
makes use of Tyr115 to lock the dimer in a conformation incompatible with DNA binding. 
Other residues can be involved in the same process and we demonstrated that the 
substitution of other residues (His7, Ser9 and Phe25) leads to a phenotype similar to the 
one obtained with NadR Y115A, regarding NadA repression and 4HPA response in vivo, 
suggesting that these amino acids can cooperate with the Tyr115.  
Taking all these observation into consideration we propose the following model for the 4-
HPA-mediated regulation of NadR (Figure 3.2.1). NadR, as other MaR regulators, has an 
intrinsic conformational flexibility and can pass from a configuration incompatible with 
DNA binding to a form able to bind DNA, spontaneously and in a reversible way. The 
binding of 4-HPA in its binding pocket may lock the position of the DNA-binding lobes in 
place by acting as a “glue” between the dimerization and the DNA-binding domains, thus 
preventing the cross-talking between the different domains of NadR which is essential to 
induce the conformational changes required for DNA interaction. The Tyr115 plays a key 
role in this cross-talking mechanism, by being involved in the transduction of the 4HPA 
binding to the responsive effects in the dimerization domain and therefore in the DNA-
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binding lobes. The substitution of the Tyr115 causes, indeed, the stacking of NadR onto the 
DNA and the inability to respond to the 4HPA inducer. The model proposed is based on 
the comparison of our data with available structural models of regulation of MarR 
homologs. The resolution of the crystal structure of NadR in its free and ligand-bound 
state would greatly facilitate our understanding of the mechanism of regulation of NadR 
by 4-HPA.  
 
Figure 3.2.1 - Model of NadR DNA binding activity regulation. 
The 4-HPA-mediated regulation of NadR on nadA is schematized here and fully described in the discussion. 
In the NadR dimer schematic model, blue ellipses, yellow circles and green ellipses represent the 
dimerization domain, the ligand binding pocket and the DNA binding lobes, respectively. The altered ligand 
pocket in the mutated form Y115A of NadR is represented by orange circles. The small molecule ligand is 
represented by a red dot.       
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We have demonstrated in the first part of the thesis that NadR regulates a regulon of 
genes in response to 4-HPA. The MafA1 adhesins are differentially regulated by NadR in 
response to 4HPA with respect to nadA. It is tempting to speculate that, while the 
conformational modification mediated by 4HPA on NadR is the same as we propose in 
our model generated on nadA, the regulatory outcome may differ due to differential 
promoter architectures and DNA binding sequences. In fact we demonstrated that, 
differentially from nadA, the Tyr115 mutant has no effect on MafA1 protein level 
expression, suggesting that the hyper-repressive activity of Y115A on the type I promoter 
of nadA comprising multiple NadR binding sites is influenced by promoter architecture 
and possibly by an altered tetramerization capacity of the mutant.  
 
3.3 Transcriptional Regulation of the nadA Gene Impacts on the 
Prediction of Coverage of the 4CMenB Vaccine 
In the third part of this work, we evaluated the role of NadR regulation on nadA 
expression during infectious disease and therefore the impact on vaccine coverage 
prediction. 
In the absence of an efficacious broadly protective vaccine, MenB is the leading cause of 
bacterial meningitis and septicemia in many industrialized countries. A novel 
multicomponent vaccine, 4CMenB, is able to induce bactericidal antibodies against strains 
expressing vaccine antigens, but because MenB clinical isolates are diverse, it is necessary 
to evaluate the potential of the vaccine to kill circulating strains and therefore the 
potential public health impact of this vaccine. The MATS assay, which assesses the 
relative contributions of the 4 major components present in the 4CMenB vaccine, 
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predicts whether a given isolate can be killed or not [274]. An evaluation using this assay 
of more than 1,000 MenB strains from 5 EU countries predicted that 73% to 87% would 
be covered by 4CMenB. However, the relative contribution of NadA to this combined 
coverage prediction appers to be low (less than 2%) [246].   
The role of NadA in eliciting bactericidal antibodies protecting against circulating strains, 
has been unclear due to NadR-mediated repression of NadA expression under the in vitro 
growth conditions used for MATS and hSBA assays, which are performed in the early 
phase of growth, when NadR represses maximally nadA expression [141]. For this reason 
it is reasonable to anticipate that nadA expression in vitro could be different than the 
level reached in the host. Litt and colleagues [205] previously showed the presence of 
antibodies that recognized recombinant NadA in children convalescing after 
meningococcal disease. Interestingly, we report here that sera from children infected by 
isolates that failed to express NadA in culture (MATS RP = 0), or express low NadA levels 
(MATs RP value < PBT) are able to recognize NadA significantly more than sera from 
subjects infected by nadA- strains (Figure 2.3.1). Taken together, these observations 
suggest that despite the low levels of NadA expression in vitro, all these strains express 
NadA in an immunogenic form in the setting of invasive disease. Furthermore, anti-NadA 
antibodies are also found in healthy individuals with levels tending to increase with age 
[275], suggesting that NadA is expressed in vivo, at a level sufficient to drive the immune 
response. NadA expression is also induced in the ex vivo model of human saliva (Figures 
2.1.6 and 2.3.4), suggesting again high expression in the niche of meningococcal 
colonization, which can be mimicked in vitro by addition of 4-HPA or 3Cl4-HPA 
representing natural inducers of NadA present in the host.  
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Using the recombinant nadR- strains and the HPA inducers as a model for in vivo 
expression, we have validated NadA as a potent immunogen in all ages and a valid target 
for protective responses. Once repression mediated by NadR is relieved and NadA is 
expressed at high levels, strains normally resistant to killing by 4CMenB immune sera are 
rendered highly susceptible to killing in SBA. The molecular mechanism of both NadR 
repression of nadA and induction mediated by HPA compounds is conserved in a wide 
panel of N. meningitidis strains belonging to different clonal complexes (Figures 2.1.5 and 
2.3.2). These observations suggest that any strain carrying nadA could potentially be 
targeted by bactericidal antibody elicited by the 4CMenB vaccine when NadR repression 
is relieved during infection. 
The ability of passively administered vaccinees’ sera to protect mice from infection of 
NGP165, and to return protective results in the modified MATS and hSBA assays, when 
NGP165 is grown in vitro with added HPA, suggests that this treatment mimics the in vivo 
status of NGP165 with respect to NadA expression. It is noteworthy that passively 
administered sera from mice immunized with NadA recombinant protein alone protect 
infant rats from infection with NGP165, demonstrating that the level of expression 
reached by NadA alone in vivo is sufficient to promote bacterial killing. Finally, a 
bioluminescent nadA-lux fusion demonstrates the induction of the nadA promoter three 
hours after infection in the infant rat model, demonstrating the expression of nadA 
during bacterimia in vivo. 
The expression of NadA in vivo in the host is in line with its putative role during 
meningococcal infection. Its adhesive role is important in the course of colonization of the 
human upper respiratory tract. Following the passage across the epithelium, 
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meningococcus invades tissues and blood, where NadA can interact with human blood 
leukocytes and lead to enhanced immune stimulation [199, 201, 276, 277]. For these 
reasons, NadA is to be considered an important meningococcal virulence factor, involved 
in progressively invasive steps of infection. In accordance with this statement we 
demonstrated here that different signals are able to modulate the NadR repressive 
activity on NadA (Figure 2.3.3). Signals present in saliva, which we can mimic by using HPA 
molecules at high concentration during in vitro growth, may mediate NadA induction 
during the colonization of the oro-pharynx. However, because NadA could be required 
during other steps of the pathogenesis, multiple signals in niches other than the pharynx 
could modulate NadA expression as soon as the bacterium passes the epithelial barrier. 
We demonstrate indeed in the infant rat model of bacteremia that NadA is expressed 
widely three hours post infection and this up-regulation could be due to molecules such 
as the 3Cl-4HPA and NO2-4HPA, which are produced by leukocytes during inflammatory 
processes [262, 278]. Furthermore, we cannot exclude that other molecules can act on 
NadR by increasing its repressive action on its targets. 
From our data, current methods used to predict coverage of strains by the 4CMenB 
vaccine are underestimating the contribution of the NadA antigen, suggesting that all 
nadA+ meningococcal strains may be susceptible to bactericidal anti-NadA antibodies 
elicited by vaccination. A more accurate prediction may be obtained by addition of 
physiologically relevant inducers to in vitro grown bacteria, resulting in similar NadA 
expression levels to those measured in ex vivo and in vivo models of infection. This study 
provides new insights into the expression of the NadA antigen during infection, which are 
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fundamental for the implementation of prophylactic strategies such as vaccines and 
evaluation of their impact on public health. 
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4 MATERIALS AND METHODS 
4.1 Bacterial strains and culture conditions 
The N. meningitidis strains used in this study include the wild type MC58, 5/99, 961-5945, 
LNP17094, B3937, M10574, M14933, NGP165 and 2996 strains, derivatives of these wild 
type strains and the previously reported clinical isolates NM036, NM037, NM066, NM067, 
NM069, NM081, NM088, NM100, NM119, NM145, NM154, NM156, NM188 and NM191 
[205]. All strains used are reported in Appendix Table 1.  
N. meningitidis strains were routinely cultured, stocked and transformed as previously 
described [279]. They were grown on GC (Difco) agar medium plates supplemented with 
Kellogg's supplement I at 37°C/5% CO2 overnight (O/N). For liquid cultures, after O/N 
grown on solid medium, few colonies were inoculated in 7 ml GC broth supplemented 
with Kellogg's supplement I to an initial optical density at 600 nm (OD600) of 0.05.  
When required erythromycin and/or chloramphenicol antibiotics were added to culture 
media at the final concentration of 5 µg/ml and 20 µg/ml, respectively,  isopropyl β-D-1-
thiogalactopyranoside (IPTG) were added to achieve final concentrations of 1 mM. 2-, 3-, 
or 4-Hydroxyphenylacetic acid (2,3, or 4-HPA), 3-Chloro-, 3-Fluoro- or 3-Bromo-4-
Hydroxyphenylacetic acid (3Cl4-HPA, 3Fl4-HPA, or 3Br4-HPA), 2,4- or 3,4-
Dihydroxyphenylacetic acid (2,4-HPA, or 3,4-HPA) in aqueous solution was added to 
culture media to achieve final concentrations of 1, 2 or 5 mM. All these compounds were 
obtained from Sigma-Aldrich with exception of the 3Br4-HPA, which was purchased from 
Chemsigma. 
4     MATERIALS AND METHODS
 
 
 
120 
 
E. coli DH5-α [280] and BL21(DE3) [281] cultures were grown in Luria–Bertani (LB) 
medium, and when required, ampicillin, chloramphenicol and/or IIPTG were added to 
achieve final concentrations of 100, 20 µg/ml and 1 mM, respectively. 
 
4.2 Construction of mutant and complementing strains 
DNA manipulations were carried out routinely as described for standard laboratory 
methods [282]. Total lysates from single colonies of all transformants were used as template 
for diagnostic PCR analysis to confirm the correct insertion by a double homologous 
recombination event. The nadA promoter was amplified and sequenced in each transformant 
to ensure that the same numbers of repeats were present as in the derivative strain. The 
NGP165 NHBA null mutant was generated as described previously [182]. 
 
4.2.1 Generation of NadR null mutant and NadR complementing strains 
The NadR mutants of the MC58, 5/99 and 961-5945 strains were previously reported 
[141] and indicated as MC-∆1843, 5/99-∆1843, 961-∆1843, respectively. The NadR 
mutants of the LNP17094, B3937, M10574 and M14933 strains were generated by 
transformation of the wildtype strains with p∆1843ko::Cm [141] and selection on 
chloramphenicol, leading to the generation of LNP-∆1843, B39-∆1843, M10-∆1843 and 
M14-∆1843 strains, respectively. 
For complementation of the MC-∆1843 NadR null mutant [141], the nadR gene under the 
control of the Ptac promoter was reinserted into the chromosome of MC-∆1843 strain 
between the converging open reading frames (ORFs) NMB1428 and NMB1429, by 
transformation with pComEryPind-nadR. pCompEryPind-nadR is a derivative plasmid of 
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the pSLComCmr [118], in which the nadR gene was amplified from the MC58 genome 
with the primer pair 1843-F and 1843-R2 and cloned as a 441-bp NdeI/NsiI fragment 
downstream of the Ptac promoter. The chloramphenicol resistance cassette of 
pSLComCmr was substituted with an erythromycin resistance cassette, amplified with 
primers EryXbaF and EryBamR and cloned into the XbaI-BamHI sites (Appendix Table 3), 
generating pComEryPind-nadR. This plasmid was transformed into MC-∆1843 for the 
generation of the ∆NadR_C complemented mutant strain and transformants were 
selected on erythromycin. The nadR gene in the complemented strains was expressed in an 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) inducible manner. A final concentration of 1 
mM IPTG resulted in NadR expression levels similar to that of MC58 wild type strain.  
 
4.2.2 Generation of MC58 strains expressing NadR mutated proteins 
In order to generate MC58 mutant strains expressing only amino-acid substituted forms 
of NadR, plasmids containing the sequence of nadR alternatively mutated in the codons 
coding for His7, Ser9, Asn11, Arg18, Phe25, Trp39, Arg40 and Tyr115 were constructed using the 
QuikChange II XL Site-Directed Mutagenesis Kit (Stratagene). Briefly, the nadR gene was 
mutated in the pComEry-1843 plasmid using 8 couples of mutagenic primers (H7A-F/H7A-
R, S9A-F/S9A-R, N11A-F/N11A-R, R18A-F/R18A-R, F25A-F/F25A-R W39A-F/W39A-R, R40A-
F/R40A-R and Y115A-F/Y115A-R (Appendix Table 3)). The resulting plasmids were named 
pComEry-1843H7A, -1843S9A, -1843N11A, -1843R18A, -1843F25A, -1843W39A, -
1843R40A and -1843Y115A, and contain a site-directed mutant allele of the nadR gene, in 
which the selected codons were respectively substituted by a GCG alanine codon, and 
were used for transformation of the MC-∆1843 strain. The resulting transformed strains 
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were named MC-∆1843_H7A, _S9A, _N11A, _CR18A, _F25A, _CW39A, _CR40A and 
_CY115A, respectively. The nadR wild type or mutated genes in the complemented strains 
were expressed in an Isopropyl β-D-1-thiogalactopyranoside (IPTG) inducible manner. A 
final concentration of 1 mM IPTG resulted in NadR expression levels similar to that of 
MC58 wild type strain.  
 
4.2.3 Generation of lux reporter strains 
To generate bacterial luciferase transcriptional fusions of the promoters under study at a 
chromosomal location between the two converging ORFs NMB1074 and NMB1075, 
flanked on both sides with transcriptional terminators, plasmid pSL-LuxFla for allelic 
exchange in N. meningitidis strains was constructed. Briefly, the promoterless luxCDABE 
operon and cat cassette were subcloned from pSB1075 [283] into pBleuskript II [9] as an 
EcoRI-BamHI fragment and then cloned as a 6.5 kb XhoI-BamHI fragment into pSL-furlacZ 
[94] replacing 4.7kb containing an erytromycin cassette, and fur-lacZ fusion, generating 
pSL-lux-Fla. The nadA promoter was amplified with primers NadluxF2/NadluxR2 and 
cloned as a 250 bp XhoI-KpnI fragment upstream of the luxCDABE operon generating pSL-
PnadA-lux. The pSL-lux-Fla and pSL-PnadA-lux plasmids were used for transformation of 
the MC58, and MC58-∆1843 strains generating MC58-lux, MC58-PnadA-lux, and MC58-
∆1843-lux and MC58-∆1843-PnadA-lux, respectively, for the in vitro reporter analyses, 
and the 2996 strain generating 2996-lux and 2996-PnadA-lux, respectively, for the in vivo 
reporter analysis.  
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4.3 Western blot analysis  
N. meningitidis colonies from freshly grown overnight plate cultures were resuspended in 
GC medium to an optical density at 600 nm (OD600) of 0.05 and grown at 37°C to 
logarithmic phase (OD600 of 0.5, ca. 2 hours incubation). Samples of 1 ml were harvested 
and resuspended in 1x SDS-PAGE loading buffer (50 mM Tris Cl pH 6.8, 2.5 % SDS, 0.1 % 
Bromophenol Blue, 10% glycerol, 5% beta-mercaptoethanol, 50 mM DTT), normalizing 
the concentration to a relative OD600 of 5. 
To prepare protein extracts from bacteria incubated with either different small molecules 
or human saliva, N. meningitidis colonies from overnight GC plate cultures were 
resuspended in GC to an OD600 of 0.05. Liquid cultures were grown until mid log phase 
(OD600 = 0.4), harvested and resuspended in either GC, GC + 2mM or GC + 5mM of the 
indicated molecule or 10%, 50%, 90% (V/V) human saliva in GC containing EDTA-free 
Protease Inhibitors Cocktail (Roche). Bacteria were then incubated for 1 hour with 
agitation at 37°C. 1 ml of each liquid culture was harvested and resuspended in 100 ml of 
SDS-PAGE loading buffer. When required the growth was followed by 1 hour induction at 
37°C with 1 mM IPTG. 
For Western blot analysis, 10 µg of each total protein sample in 1x SDS-PAGE loading 
buffer was separated by SDS-PAGE, and transferred onto nitrocellulose membrane using 
an iBlot Dry Blotting System (Invitrogen). Membranes were blocked overnight at 4° C by 
agitation in blocking solution (10% skimmed milk, 0.05% Tween-20, in PBS) and incubated 
for 90 min at 37°C with primary antibodies (anti-NadA [203], anti-NadR [141], anti-Maf 
[254], anti-fHbp [234] and anti-Hfq [284] polyclonal sera) in 3% skim milk blocking 
solution. After washing, the membranes were incubated in a 1:2000 dilution of 
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peroxidase-conjugated anti-rabbit immunoglobulin (Biorad) or anti-mouse 
immunoglobulin (Dako) in 3% skim milk  blocking solution for 1 hour at room temperature 
and the resulting signal was detected using either the Supersignal West Pico 
chemiluminescent substrate (Pierce) or the Western Lightning-ECL chemiluminescent 
substrate (Perkin-Elmer). Quantification of the signals from western blots bands was 
performed by using a PhosphorImager and ImageQuant software (Molecular Dynamics). 
 
4.4 Protein expression and purification 
The expression and purification of the NadR recombinant protein were carried out as fully 
described previously [141]. For expression and purification of NadR mutated proteins, the 
sequence of nadR was mutated in the expression plasmid pET15-1843 [141] as described 
above using the QuikChange II XL Site-Directed Mutagenesis Kit (Stratagene) and the 
mutagenic primers pairs R18A-F/R18A-R, W39A-F/W39A-R, R40A-F/R40A-R and Y115A-
F/Y115A-R (Appendix Table 3). The resulting pET15-1843R18A, -1843W39A, -1843R40A 
and -1843Y115A vectors were subsequently transformed into E. coli BL21(DE3) strain for 
protein expression and purification. Fractions containing the purified proteins were 
analyzed by SDS-PAGE, pooled and dialyzed overnight against 50 mM Tris-HCl pH 8.0, 300 
mM NaCl using a 10-kDa molecular weight cutoff dialysis membrane (Slide-A-lyzer dialysis 
cassettes, Pierce). The 6xHisTag was cleaved at room temperature using thrombin 
agarose resin (Sigma Aldrich) and removed with the Ni-NTA matrix. The purity and the 
identity of each protein were verified by SDS-PAGE and mass spectrometry and the 
concentrations were measured using the Bradford assay. Purified proteins were 
aliquoted, flash frozen in ethanol/dry ice and stored at -80°C until use.  
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4.5 Electromobility shift assays (EMSA).  
For gel shift experiments, a probe corresponding to the respective promoter region (150-
280 bp) of the first gene in probable operons containing NadR target genes was amplified 
using primers listed in Appendix Table 3 and named with P (for promoter) and a number 
according to the NMB annotation. Two probes spanning from -170 to -116 (OpI) and -9 to 
+81 (OpII) with respect to the MC58 nadA promoter were amplified using Nad-N2/gpr-R 
and Nad-N5/Nad-Sp primer pairs respectively, to perform experiments on single NadR 
binding sites of nadA. Two pmoles of each fragment were then radioactively labeled at 
their 5’ ends with 30 µCi of (γ-32P)-ATP (6000 Ci/mmol; NEN) using 10 U of T4 
polynucleotide kinase (New England Biolabs) and used at the final concentration of 1.6 
nM. The unincorporated radioactive nucleotides were removed using TE-10 chromaspin 
columns (Clontech).  
For each binding reaction, 40 fmoles of labeled probe were incubated with recombinant 
NadR wild type or NadR mutant proteins, suspended in Protein Solution (5 mM Tris-HCl 
pH 8, 60 mM NaCl), in 25 µl final volume of Gelshift Binding Buffer (40 mM Tris-HCl pH 8, 
5 mM MgCl2, 50 mM KCl, 0.05% NP40, 10% glycerol) with 30 nM salmon sperm DNA as 
non-specific competitor. for 15 min at room temperature, and run on 6% native 
polyacrylamide gels buffered with 0.5 x TBE, at 100 Volts for 90-180 min at 4°C. When 
indicated, 1, 2, 5 or 10 mM 4-HPA was added to 100 ng of recombinant NadR WT or NadR 
mutant proteins in the binding reaction, to test the proteins responses to 4-HPA. Gels 
were dried and exposed to autoradiographic films at –80°C. To assess the specificity of 
binding of NadR on the DNA labeled probes, 1.6 nM, 8 nM and 40 nM (1-, 5- or 25-fold 
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respect to the probe) of either salmon sperm DNA or cold DNA probes were added as 
non-specific or specific competitors, respectively.  
EMSA bands radioactivity was quantified using a phosphorimager and the Image Quant 
software (Molecular Dynamics). 
 
4.6 DNAse I footprint 
The nadR, putA and mafA1 promoter regions were amplified with the primer couples 
P1843-F2/P1843-sR2, P401-F3/P401-R, P375-F/P375-652R, respectively. The PCR products 
were purified and cloned into pGEMT vector (Promega) as 258, 280 and 267 bp fragments 
generating pGEMT-P1843, pGEMT-P401 and pGEMT-P375.  2 pmols of each plasmid were 
5’ end-labeled by T4 polynucleotide kinase with [γ-32P]-ATP after digestion at either the 
NcoI or SpeI site of the pGEMT polylinker. Following a second digestion with either SpeI 
or NcoI respectively, the labeled probes were separated from the linearised vector by 
polyacrylamide gel electrophoresis (PAGE) as described previously [141]. DNA-protein 
binding reactions were carried out for 15 minutes at RT in footprint buffer (10 mM Tris 
HCl pH 8, 50 mM NaCl, 10 mM KCl, 5 mM MgCl2 10% glycerol and 0.05% NP40) containing 
40 fmol of labeled probe, 200 ng of sonicated salmon sperm as the non-specific 
competitor and nM concentrations of NadR purified protein as indicated in the figures. 
Samples were then treated with 0.03 U of DNase I (Roche) for 1 minute at RT. DNase I 
digestions were stopped, samples were purified, loaded and run on 8M urea-6% 
polyacrilamide gels as described [285]. A G+A sequence reaction was performed [286] for 
each probe and run in parallel to the fooprinting reactions.  
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4.7 3C mutation scanning  
To perform the 3C mutation scanning of the single NadR binding sites on the nadA and 
mafA1 promoters, DNA oligos corresponding to the forward and reverse strands of either 
the wild type NadR-protected sequences from DNAI footprints or to mutated sequences, 
in which sequential triplicate nucleotides were substituted with CCC, were ordered from 
Sigma. 100 pmols of each oligonucleotide pair were annealed in annealing buffer (10 mM 
Tris HCl pH 8, 50 mM NaCl and 1 mM EDTA) by using a standard thermal cycler. The mix 
was heated to 95°C and left at this temperature for 5 minutes, followed by ramp cooling 
to 25°C over a period of 45 minutes. The annealed oligos were stored at -20°C, 5’ end 
labeled and submitted to EMSA analysis as described in the previous section.     
 
4.8 RNA samples preparation  
Bacterial cultures were grown in GC liquid medium to an OD600 of 0.5 and then added to 
the same volume of frozen media to bring the temperature immediately to 4° C. Total 
RNA was isolated using an RNeasy kit (Qiagen) as described by the manufacturer. RNA 
pools for microarray experiments were prepared from 3 independent cultures of bacteria. 
Total RNA was extracted separately from each bacterial pellet and 15 µg of each 
preparation were pooled together. Three independent pools were prepared for each 
condition. 
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4.9 Microarray analyses 
DNA microarray analysis was performed using an Agilent custom-designed 
oligonucleotide array as previously described [252]. cDNA probes were prepared from 
RNA pools (5 µg) obtained from MC58 wildtype and MC-∆1843 null mutant cells (see 
above) and hybridized as described by Fantappiè and colleagues [252]. Three 
hybridizations were performed using cDNA probes from three independent MC58 and 
MC-∆1843 pools, respectively, and the corresponding dyeswap experiments (with MC58 
and MC-∆1843 pools inversely labeled with the Cy3 and Cy5 fluorophores) were also 
performed. Differentially expressed genes were assessed by grouping all log2 ratio of the 
Cy5 and Cy3 values corresponding to each gene, within experimental replicas and spot 
replicas, and comparing them against the zero value by Student’s t-test statistics (one 
tail).  
The array layout was submitted to the EBI ArrayExpress and it is available with the 
identifier A-MEXP-1967. The entire set of supporting microarray data has been deposited 
in the ArrayExpress public database under the accession number E-MTAB-803.  
 
4.10 Quantitative Real Time PCR (qRT-PCR) 
Approximately 4 µg of the total RNA preparation was treated with RQ1 RNase-free DNase 
(Promega). RNA was then reverse transcribed using random hexamer primers and 
Moloney murine leukemia virus reverse transcriptase (Promega) as recommended by the 
manufacturer. For negative controls, all RNA samples were also incubated without 
reverse transcriptase. Primer pairs for each target gene were designed and optimized and 
are listed in Appendix Table 3 named with the number according to their NMB annotation 
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and rt for RT-PCR. Primers 16S_F and 16S_R were used for the 16S rRNA normalization 
control (Appendix Table 3). All RT-PCRs were performed in triplicate using a 25 µl mixture 
containing cDNA (5 µl of a 1/5 dilution), 1x brilliant SYBR green quantitative PCR master 
mixture (Stratagene), and approximately 5 pmol of each primer. Amplification and 
detection of specific products were performed with an Mx3000 real-time PCR system 
(Stratagene) using the following procedure: 95°C for 10 min, followed by 40 cycles of 95°C 
for 30 s, 55°C for 1 min, and 72°C for 30 s and then a dissociation curve analysis. The 16S 
rRNA gene was used as the endogenous reference control, and relative gene expression 
was determined using the 2-∆∆Ct relative quantification method. 
 
4.11 Human saliva samples  
Human saliva was obtained from healthy non-smoking donors in the morning at least ten 
hours after eating and after rinsing the mouth with water. In order to minimize the 
degradation of the proteins the sample was kept on ice during the collection process. 
Immediately after collection, the sample of human saliva was stored at -20°C.  
 
4.12 Human serum samples 
Healthy human volunteers were immunized under informed consent with the 
experimental serogroup B vaccine containing 50 μg each of GNA2091-fHbp, NHBA-
GNA1030, and NadA and 25 μg of Outer Membrane Vesicles from the New Zealand strain 
NZ98/254, adsorbed to aluminium hydroxide. Serum samples before and after 
immunization were obtained from the following clinical trials: 
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Study 1 was a clinical trial conducted in healthy adults, laboratory workers. Pooled sera 
were derived from 23 subjects before and after 3 doses of 4CMenB at 0, 2 and 6 months. 
Study 2 was a clinical study evaluating the safety, immunogenicity and lot consistency of 
4CMenB administered to infants at 2, 4 and 6 months of age. Extensions of this clinical 
study investigated a fourth (booster) dose at 12 months of age. Pooled sera were derived 
from 107 infants at 7 months of age who received the primary series of 3 doses of routine 
vaccine at 2, 4 and 6 month of age and from 141 infants who received the primary series 
of 3 doses of 4CMenB at 2, 4 and 6 month of age plus a booster in the second year of life.  
Study 3 was a clinical study evaluating the safety, tolerability and immunogenicity of 
4CMenB administered to infants at 2, 4 and 6 months of age. Extensions of this clinical 
study investigated a fourth (booster) dose at 12, 18 or 24 months of age. Pooled sera 
were derived from 109 infants at 5 months of age who received the primary series of 3 
doses of routine vaccine at 2, 3 and 4 month of age and from 69 infants who received the 
primary series of 3 doses of 4CMenB at 2, 4 and 6 months of age plus a booster in the 
second year of life.  
 
4.13 Immunization of mice 
To prepare antisera, 20 μg of individual antigens NadA, NHBA-GNA1030, GNA2091-fHbp 
or a combination of 20 μg of each of NHBA-GNA1030, GNA2091-fHbp and NadA with or 
without 10 μg of deoxycholate-extracted OMV derived from the strain NZ98/254 were 
used to immunize 6-week-old CD1 female mice (Charles River). Five to ten mice per group 
were used. The antigens were administered intraperitoneally (i.p.), together with 
aluminium hydroxide (3 mg/ml) on days 0, 21 and 35. 
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4.14 Serum bactericidal assay (SBA) 
Serum bactericidal antibody activity against Neisseria meningitidis strains with mice 
antisera was evaluated as previously described [287] with pooled baby rabbit serum used 
as the complement source (rSBA). Serum bactericidal antibody assays with human 
complement (hSBA) were performed as described by Borrow et al. with minor 
modifications [287]. MenB bacteria were subcultured overnight on Chocolate Agar and 
resuspended in Mueller Hinton medium (MHM) to an OD600 of 0.25 before use in the 
assay. Serum bactericidal titers were determined as the last dilution that resulted in at 
least a 50% reduction in colony forming units (CFU) relative to the number of CFU present 
at the beginning of the bactericidal reaction (i.e. 50% of T0). Human plasma obtained 
from volunteer donors after informed consent was selected for use as complement 
source with a particular MenB strain only if it did not significantly reduce CFU of that 
strain relative to T0 when added to the assay at a final concentration of 50%. The final 
assay mixture contained 25% human plasma complement. When required, 4-HPA and 
3Cl4-HPA in aqueous solution were added to chocolate agar at a final concentration of 5 
mM.  
 
4.15 Meningococcal Antigen Typing System (MATS) ELISA  
The MATS assay was been performed as previously described [243]. Briefly, bacteria are 
grown overnight on Chocolate Agar plates (Biomerieux) ± 4-HPA and 3Cl4-HPA 
supplementation. Bacterial suspensions are prepared from overnight cultures, single 
colonies being collected and suspended to an OD600 = 0.4, using Ultrospec 10 Classic 
(Amersham Biosciences). Bacterial suspensions are lysed with a detergent (EmpigenBB 
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5%, Sigma) added to 1/10 volume, followed by incubationfor 1 hour at 45°C in a shaking 
water bath. Samples are added to ELISA microwell plates, which were previously coated 
with polyclonal rabbit antibody against NadA (961c) to capture the antigen from the 
lysate, and diluted at 2-fold step dilution.  Captured antigen is then detected with a 
biotin-labeled rabbit antibody (Biotin-Ab) against the antigen followed by HRP-labeled 
streptavidin. The signal is provided by reduction of o-phenylenediamine substrate (OPD, 
Sigma). Each plate contains 1 reference strain and 6 sample strains: 5/99 is used as the 
reference strain for NadA. Relative Potency is a mathematically-determined quantity 
obtained by comparing the serial dilution curves of the test sample and the reference 
strain. Raw data reduction and analysis is performed by StatLIA (Brendan Technologies). 
 
4.16 Passive protection and in vivo imaging in infant rats. 
The ability of anti-NadA antibodies to confer passive protection against N. meningitidis 
bacteremia was tested in infant rats challenged intraperitoneally (i.p.). In vivo imaging of 
the bioluminescence of the PnadA-lux reporter and control strains was monitored in 
infant rats infected i.p. The day before the challenge/infection, freshly thawed bacteria 
were inoculated onto chocolate agar and were grown overnight at 37°C in 5% CO2. On the 
morning of the challenge/infection, several colonies were inoculated in MHM 
supplemented with 0.25% (wt/vol) glucose to a starting OD600 of∼0.05. After 1.5 h growth 
at 37°C in 5% CO2, the bacterial suspension reached an OD600 of ∼0.25 and was diluted in 
PBS to obtain 105-107 CFU/ml. 5–7-day-old pups from litters of out-bred Wistar rats 
(Charles River) were numbered. The protection and challenge were performed as follows: 
Groups of 3–19 animals were treated i.p. at time 0 with 100 µl doses of different dilutions 
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of test or control antisera. Three hours later, the animals were challenged i.p. with a 
100µl dose of 105 CFU of N. meningitidis strain NGP165. Eighteen hours after the bacterial 
challenge, blood samples were obtained by cheek puncture with a syringe containing 25U 
of heparin without preservative (American Pharmaceutical Partnersand CFUs were 
measured. Rats were considered infected when >10 CFUs were counted on plates 
carrying 100 µl of blood. Counts above the threshold were verified for positivity by 
examining plates carrying 10- and 100-fold dilutions of blood. For in vivo imaging of 
bioluminescent reporters, groups of 5 animals were inoculated i.p. at time 0 with 100 µl 
doses of 104 CFU of the 2996-lux or 2996-Pnad-lux strains. Rats were then anesthetized 
using a constant flow of 2.5% isoflurane mixed with oxygen. Bioluminescence 
measurements of ventral views of each group of rats were taken of at time 0, 3 and 24 
hours, using a an IVIS 100 system (Xenogen Corp., Alameda, CA) according to instructions 
from the manufacturer. Analysis and acquisition were performed using Living Image 3.1 
software (Xenogen Corp.). Quantifying was performed using the photons per second 
emitted by each rat. 2 rats infected with the 2996 wild type strain under the same 
conditions of acquisition were used for subtracting the background. Twenty four hours 
after infection, blood samples were obtained and CFU counts measured.  
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5 APPENDIX 
5.1 Table 1 - Strains used in this study 
Strains Relevant characteristics Reference 
N.meningitidis   
MC58 Clinical isolate, sequenced strain containing 9 TAAA tetranucleotide repeats in the nadA promoter, CC32 [62] 
5/99 Clinical isolate containing 8 TAAA tetranucleotide repeats in the nadA promoter, CC8 NIPH1 
961-5945 Clinical isolate containing 12 TAAA tetranucleotide repeats in the nadA promoter, CC8 [203] 
LNP17094 Clinical isolate containing 12 TAAA tetranucleotide repeats in the nadA promoter, CC32 [243] 
B3937 Clinical isolate containing 12 TAAA tetranucleotide repeats in the nadA promoter, CC18 [243] 
M10574 Clinical isolate containing 6 TAAA tetranucleotide repeats in the nadA promoter, CC32 CDC2 
M14933 Clinical isolate containing 6 TAAA tetranucleotide repeats in the nadA promoter, CC32 CDC2 
NGP165 Clinical isolate containing 9 TAAA tetranucleotide repeats in the nadA promoter, CC11 [243] 
2996 Clinical isolate, CC8 [243] 
NM036 Strain carrying the nadA gene from a collection of 31 clinical isolates from children ≤ 4 years of age, convalescing after meniningococcal disease [205] 
NM037 Strain carrying the nadA gene from a collection of 31 clinical isolates from children ≤ 4 years of age, convalescing after meniningococcal disease  [205] 
NM066 Strain carrying the nadA gene from a collection of 31 clinical isolates from children ≤ 4 years of age, convalescing after meniningococcal disease [205] 
NM067 Strain carrying the nadA gene from a collection of 31 clinical isolates from children ≤ 4 years of age, convalescing after meniningococcal disease [205] 
NM069 Strain carrying the nadA gene from a collection of 31 clinical isolates from children ≤ 4 years of age, convalescing after meniningococcal disease [205] 
NM081 Strain carrying the nadA gene from a collection of 31 clinical isolates from children ≤ 4 years of age, convalescing after meniningococcal disease [205] 
NM088 Strain carrying the nadA gene from a collection of 31 clinical isolates from children ≤ 4 years of age, convalescing after meniningococcal disease [205] 
NM100 Strain carrying the nadA gene from a collection of 31 clinical isolates from children ≤ 4 years of age, convalescing after meniningococcal disease [205] 
NM119 Strain carrying the nadA gene from a collection of 31 clinical isolates from children ≤ 4 years of age, convalescing after meniningococcal disease [205] 
NM145 Strain carrying the nadA gene from a collection of 31 clinical isolates from children ≤ 4 years of age, convalescing after meniningococcal disease [205] 
NM154 Strain carrying the nadA gene from a collection of 31 clinical isolates from children ≤ 4 years of age, convalescing after meniningococcal disease [205] 
NM156 Strain carrying the nadA gene from a collection of 31 clinical isolates from children ≤ 4 years of age, convalescing after meniningococcal disease [205] 
NM188 Strain carrying the nadA gene from a collection of 31 clinical isolates from children ≤ 4 years of age, convalescing after meniningococcal disease [205] 
NM191 Strain carrying the nadA gene from a collection of 31 clinical isolates from children ≤ 4 years of age, convalescing after meniningococcal disease [205] 
MC-∆1843::CmR NadR null mutant in MC58 strain, generated with the p∆1843ko::CmR plasmid, CmR  [141] 
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MC-∆1843::KanR NadR null mutant in MC58 strain, generated with the p∆1843ko::KanR plasmid, KanR  This study 
5/99-∆1843 NadR null mutant in 5/99 strain, generated with the p∆1843ko::CmR plasmid, CmR [141] 
961-∆1843 NadR null mutant in 961-5945 strain, generated with the p∆1843ko::CmR plasmid, CmR [141] 
LNP-∆1843 NadR null mutant in LNP17094 strain, generated with the p∆1843ko::CmR plasmid, CmR This study 
B39-∆1843 NadR null mutant in B3937 strain, generated with the p∆1843ko::CmR plasmid, CmR This study 
M10-∆1843 NadR null mutant in M10574 strain, generated with the p∆1843ko::CmR plasmid, CmR This study 
M14-∆1843 NadR null mutant in M14933 strain, generated with the p∆1843ko::CmR plasmid, CmR This study 
MC-∆1843_C MC-∆1843::CmR derivative, NadR complemented strain expressing the nadR wild type gene under the control of the inducible Ptac promoter 
between the converging open reading frames NMB1428 and NMB1429, CmR and EryR 
This study 
MC-∆1843_CH7A MC-∆1843::CmR derivative, NadR complemented strain expressing the nadR H7A mutant gene, CmR and EryR This study 
MC-∆1843_CS9A MC-∆1843::CmR derivative, NadR complemented strain expressing the nadR S9A mutant gene, CmR and EryR This study 
MC-∆1843_CN11A MC-∆1843::CmR derivative, NadR complemented strain expressing the nadR N11A mutant gene, CmR and EryR This study 
MC-∆1843_CR18A MC-∆1843::CmR derivative, NadR complemented strain expressing the nadR R18A mutant gene, CmR and EryR This study 
MC-∆1843_CF25A MC-∆1843::CmR derivative, NadR complemented strain expressing the nadR F25A mutant gene, CmR and EryR This study 
MC-∆1843_CW39A MC-∆1843::CmR derivative, NadR complemented strain expressing the nadR W39A mutant gene, CmR and EryR This study 
MC-∆1843_CR40A MC-∆1843::CmR derivative, NadR complemented strain expressing the nadR R40A mutant gene, CmR and EryR This study 
MC-∆1843_CY115A MC-∆1843::CmR derivative, NadR complemented strain expressing the nadR Y115A mutant gene, CmR and EryR This study 
MC58-lux MC58 derivative, carrying the promoterless lux operon, CmR  This study 
MC58-PnadA-lux MC58 derivative, carrying the lux operon under the control of the promoter of NadA with 9 TAAA tetranucleotide repeats, CmR This study 
MC58-∆1843-lux MC-∆1843::KanR derivative, carrying the promoterless lux operon, KanR and CmR This study 
MC58-∆1843-PnadA-lux MC-∆1843::KanR derivative, carrying the lux operon under the control of the promoter of NadA with 9 TAAA tetranucleotide repeats, KanR and CmR This study 
2996-lux 2996 derivative, carrying the promoterless lux operon, CmR This study 
2996-PnadA-lux 2996 derivative, carrying the lux operon under the control of the promoter of NadA with 9 TAAA tetranucleotide repeats, CmR This study 
E.coli   
DH5-α supE44 hsdR17 recA1 endA1 gyrA96 thi-1 relA1 [288] 
BL21(DE3) hsdS gal (λcIts857 ind1 Sam7 nin-5 lacUV5-T7 gene 1) [281] 
BL21(DE3)-1843R18A BL21(DE3) derivative strain carrying the pET15-1843R18A plasmid for expression and purification of the mutated NadR, AmpR This study 
BL21(DE3)-1843RW39A BL21(DE3) derivative strain carrying the pET15-1843 W39A plasmid for expression and purification of the mutated NadR, AmpR This study 
BL21(DE3)-1843R40A BL21(DE3) derivative strain carrying the pET15-1843 R40A plasmid for expression and purification of the mutated NadR, AmpR This study 
BL21(DE3)-1843Y115A BL21(DE3) derivative strain carrying the pET15-1843 Y115A plasmid for expression and purification of the mutated NadR, AmpR This study 
1 The Norwegian Institute of Public Health 
2 Centers for Disease Control and Prevention 
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5.2 Table 2 - Plasmids used in this study 
Plasmid Relevant characteristics Reference 
pET15b Expression vector for N-terminal His tagged proteins, AmpR Invitrogen 
pET15-1843 pET15b derivative for expression of recombinant 1843 protein, AmpR [141] 
pET15-1843R18A pET15-1843 derivative for expression of recombinant 1843-R18A mutant protein, AmpR This study 
pET15-1843W39A pET15-1843 derivative for expression of recombinant 1843-W39A mutant protein, AmpR This study 
pET15-1843R40A pET15-1843 derivative for expression of recombinant 1843-R40A mutant protein, AmpR This study 
pET15-1843Y115A pET15-1843 derivative for expression of recombinant 1843-Y115A mutant protein, AmpR This study 
pGEM-T E.coli cloning vector, AmpR Promega 
p∆1843ko::CmR Construct for generating knockout of the NMB1843 gene, CmR [141] 
p∆1843ko::KanR Construct for generating knockout of the NMB1843 gene, KanR This study 
pSLComCmr Plasmid consisting of the chloramphenicol resistance gene flanked by upstream and downstream regions for allelic replacement at a 
chromosomal location between ORFs NMB1428 and NMB1429, CmR 
[118] 
pComEryPind-NadR Plasmid for complementation of the NadR null mutant, derivative of pSLComCmr containing a copy of the nadr  gene under the control of the Ptac 
promoter, EryR 
This study 
pComEry-1843H7A Plasmid for complementation of the NadR null mutant with the H7A mutant form of nadR, derivative of pComEry-NadR, EryR This study 
pComEry-1843S9A Plasmid for complementation of the NadR null mutant with the S9A mutant form of nadR, derivative of pComEry-NadR, EryR This study 
pComEry-1843N11A Plasmid for complementation of the NadR null mutant with the N11A mutant form of nadR, derivative of pComEry-NadR, EryR This study 
pComEry-184 R18A Plasmid for complementation of the NadR null mutant with the R18A mutant form of nadR, derivative of pComEry-NadR, EryR This study 
pComEry-1843F25A Plasmid for complementation of the NadR null mutant with the F25A mutant form of nadR, derivative of pComEry-NadR, EryR This study 
pComEry-1843W39A Plasmid for complementation of the NadR null mutant with the W39A mutant form of nadR, derivative of pComEry-NadR, EryR This study 
pComEry-1843R40A Plasmid for complementation of the NadR null mutant with the R40A mutant form of nadR, derivative of pComEry-NadR, EryR This study 
pComEry-1843Y115A Plasmid for complementation of the NadR null mutant with the Y115A mutant form of nadR, derivative of pComEry-NadR, EryR This study 
pSB1075  N-acyl homoserine lactone biosensor based on lasR::lasI’luxCDABE, AmpR [283] 
pBleuskcript II E. coli cloning and expression vector, AmpR [9] 
pSL-furlacZ  Plasmid containing upstream and downstream regions for allelic replacement at a chromosomal location between ORFs NMB1074 and NMB1075, 
EryR 
[94] 
pSL-lux-Fla pSL-furlacZ derivative with the promoterless luxCDABE operon and a chloramphenicol cassette, CmR This study 
pSL-PnadA-lux pSL-lux-Fla derivative with the luxCDABE operon under the control of the promoter of nadA and a chloramphenicol cassette, CmR This study 
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5.3 Table 3 - Oligonucleotides used in this study 
Name Sequence1 Site 
1843-F attcacatATG NdeI CCTACCCAATCAAAACATGCG 
1843-R2 attcatgcat NsiI CGGCGTATTACGAGTTCAACGCATCCTCG 
EryXbaF attcgtctaga XbaI GCAAACTTAAGAGTGTGTTGATAG 
EryBamR atatatggatcc BamHI GGGACCTCTTTAGCTTCTTGG 
NadluxF2 attcactcgaggctagc XhoI-NheI TAAGACACGACACCGGCAGAATTG                    
NadluxR2 attcaggtacc KpnI TACGCTCATTACCTTTGTGAGTGG 
119rt-R AGTGTTGCCCTGTGTAGCAG  
120rt-F GCATGGATTATAACCTATCGATCTAA  
120rt-R TACGCTTGCTGTTCCCTGT  
207rt-F TGACCAAATTCGACACCGT  
207rt-R ATCGACACCGAGTTCTTTCC  
401rt-L AGGTATCGGTTTCGTTGTCC  
401rt-R TTGATTTCGCTGTCCCAATA  
652-375rt-F CGAATATTTCGCCGTTGAC  
652-375rt-R AAAGGGCGTATTGTTCTTGG  
702rt-F GATTTGCTGCTGTCGGACTA  
702rt-R GCCTATCCCGTTGGATAATG  
865rt-F ACCGCTGGTGGTATGATAGG  
865rt-R GCACCATTTGCACGAATAAC  
955rt-F TGTGCCGGTCAGGTTTACTA  
955rt-R GTTCGGATATTTCGCCAGTT  
978rt-F AAACACAAGCTCAACGCACT  
978rt-R GGGCAATCAGGGTCATAATC  
980rt-F TTTGAAACCGTTGTCGAAAG  
980rt-R GGCGCGTTGACCTTATAAAT  
1277rt-F AGACGCAGGAGCAGGATATT  
1277rt-R CCGTATTCTTCCGAAAGCTC  
1476rt-F ACGTTGCCATTTACAACGAA  
1476rt-R GTTCGGCGTTGGTAATTTCT  
1478rt-F CATCGGCAAACTGGTTCA  
1478rt-R CTCAAATGGTCGCGGTAGTA  
1609rt-F TACTACACCGGATTGTCCGA  
1609rt-R CTTCTTGATCGGCAACTTCA  
1841rt-F CCTTTGACCGATACCACTCC  
1841rt-R ATGACGATTTCGGTAAACCC  
1842rt-F TTTCAAACTTCGTTCCGTGA  
1842rt-R CCGTCATTGTAATGCCGTAA  
1843rt-F AGGGCGAGAAGCTGTATGAG  
1843rt-R CAGGTCTTTAAGCAGCAGCA  
1844rt-F ATGCGGTTTATAGCGTATTG  
1844rt-R TTAAGTCTCCAAGTTATCG  
1994rt-F GCTGGCACAGCTAATACTGC  
1994rt-R TCAGCTTTGTTCGTAGCGAT  
2099rt-F ACCTGCCTTATATCGAACCG  
2099rt-R AGGTTCAAATCATGCACACG  
16S_F ACGGAGGGTGCGAGCGTTAATC  
16S_R CTGCCTTCGCCTTCGGTATTCCT  
P207-F2 CTCAAACAATACAAAGCCAAACAGG  
P207-R GCCCATGGTTTGTTCCTTTGTTGAGGG  
P375-F CCGCAATGGGTGGAAGCCGCCGC  
P652-F ACAGTCAAAATGCCGTCTGAAAGCC  
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P375-652R GGAGGAGCAGGGTTTTCATAGCGGGG  
P401-F3 GCCGACGCAGATTACCGCGCC  
P401-R GCCGGAAATGCAAAATGAAACATTTTTTGG  
P0430-F CAAAGGAACATTACTATGAAACC  
P0430-R GTGTTGACTCATCATATTTCTCC  
P0535-F CGGGCATACGACATTCTTTCCGC  
P0535-R GACATTTCTTAACGGCAATGC  
P0702-F CCCTGAGTCCTAGATTCCCGC  
P0702-R CCGAAAAACCGTCATAACAAGATTTG  
P0955-F2 TACCGGTTCGGAACGCCGCG  
P0955-R CGTCCATCATGGCGTGCGC  
P0978-F2 CGGCACACGCAACCGGCAATGCGGCGC  
P0978-R CGAGTCCTGAAGACATAGAAATTCTCCG  
P0980-F2 CGGCAAAGAATGTTACGGCGGGCGG  
P0980-R CGCGTGGGATACCGATTTTCATCTCTG  
P1205-F CCAACGAAGAACATATAGACTGGCTGG  
P1205-R CAAGCACCCTGAATTTCATATCGG  
P1277-F CCGGCGTTAAACGCCCCG  
P1277-R CAGACAGGGACAAACCTTCTCACTCC  
P1476-F2 GCAAATCCCGGCGCCGTTCC  
P1476-R GGGCTTCAGACATTTTGCTTCC  
P1478-F2 CAAGCCGCACGGAATCCGTCTG  
P1478-R CGATGGCTGCATTCATAATCCGG  
P1609-F CCTATCAGCTCCAGCAGATGC  
P1609-R GCTCATCGGTGATTCCTCGG  
P1843-F2 GAGCCGACGCGCCTGCCGATG  
P1843-sR2 GGTAGGCATTGTTTAAGTCTC  
1844-F GGGAAAGAGCCGACGCGCCTG  
1844-R GCTATAAACCGCATCGGACGACTGG  
P2099-F CCGCCTGTTCCTGCTGCC  
P2099-R CCTCGTTCCTCATTTCAGACGGCC  
Nad-N1 attcagatgcat NsiI GACGTCGACGTCCTCGATTACGAAGGC 
Nad-B1 attcaggatcc BamHI tacGCTCATTACCTTTGTGAGTGG 
Nad-N2 attcagatgcat NsiI TAAGACACGACACCGGCAGAATTG 
gpr-R gattagcatgc SphI CGGCATTAATATCTGTTAATATGTGC 
Nad-N5 attcagatgcat NsiI CTTTAATATGTAAACAAACTTGGTGG 
Nad-Sp attcagcatgc SphI tacGCTCATTACCTTTGTGAGTGG 
H7A-F TGCCTACCCAATCAAAAgcgGCGTCTATCAATATCGG  
H7A-R CCGATATTGATAGACGCcgcTTTTGATTGGGTAGGCA  
S9A-F CCCAATCAAAACATGCGgCgATCAATATCGGTCTGATAC  
S9A-R GTATCAGACCGATATTGATcGcCGCATGTTTTGATTGGG  
N11A-F CAAAACATGCGTCTATCgcgATCGGTCTGATACAGGC  
N11A-R GCCTGTATCAGACCGATcgcGATAGACGCATGTTTTG  
R18A-F CGGTCTGATACAGGCAgcGGAAGCCCTG  
R18A-R CAGGGCTTCCgcTGCCTGTATCAGACCG  
F25A-F GAAGCCCTGATGACCCAAgcCAGGCCTATTCTGAATCAG  
F25A-R CTGATTCAGAATAGGCCTGgcTTGGGTCATCAGGGCTTC  
W39A-F CCGATCAGCAAgcGCGGATTATCCGTC  
W39A-R GACGGATAATCCGCgcTTGCTGATCGG  
R40A-F CCGATCAGCAATGGgcGATTATCCGTC  
R40A-R GACGGATAATCgcCCATTGCTGATCGG  
Y115A-F GTGGACGAACGCgcCGACGCTATCGAGG  
Y115A-R CCTCGATAGCGTCGgcGCGTTCGTCCAC  
NadA OP1 F GCATAATATGCACATATTAACA            
NadA OP1 R TGTTAATATGTGCATATTATGC            
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NadA OP2 F TATATACTTTAATATGTAAACA             
NadA OP2 R TGTTTACATATTAAAGTATATA             
MafA OP F ACTCAAAATCCGTTCAACATCAAACAAA         
MafA OP R TTTGTTTGATGTTGAACGGATTTTGAGT        
NadA1mut1F cccTAATATGCACATATTAACA            
NadA1mut1R TGTTAATATGTGCATATTAggg            
NadA1mut2F GCAcccTATGCACATATTAACA            
NadA1mut2R TGTTAATATGTGCATAgggTGC            
NadA1mut3F GCATAAcccGCACATATTAACA            
NadA1mut3R TGTTAATATGTGCgggTTATGC            
NadA1mut4F GCATAATATcccCATATTAACA            
NadA1mut4R TGTTAATATGgggATATTATGC            
NadA1mut5F GCATAATATGCAcccATTAACA            
NadA1mut5R TGTTAATgggTGCATATTATGC            
NadA1mut6F GCATAATATGCACATcccAACA            
NadA1mut6R TGTTgggATGTGCATATTATGC            
NadA1mut7F GCATAATATGCACATATTcccA            
NadA1mut7R TgggAATATGTGCATATTATGC            
MafAmut1F cccCAAAATCCGTTCAACATCAAACAAA          
MafAmut1R TTTGTTTGATGTTGAACGGATTTTGggg        
MafAmut2F ACTcccAATCCGTTCAACATCAAACAAA          
MafAmut2R TTTGTTTGATGTTGAACGGATTgggAGT        
MafAmut3F ACTCAAcccCCGTTCAACATCAAACAAA          
MafAmut3R TTTGTTTGATGTTGAACGGgggTTGAGT        
MafAmut4F ACTCAAAATcccTTCAACATCAAACAAA          
MafAmut4R TTTGTTTGATGTTGAAgggATTTTGAGT        
MafAmut5F ACTCAAAATCCGcccAACATCAAACAAA          
MafAmut5R TTTGTTTGATGTTgggCGGATTTTGAGT        
MafAmut6F ACTCAAAATCCGTTCcccATCAAACAAA          
MafAmut6R TTTGTTTGATgggGAACGGATTTTGAGT        
MafAmut7F ACTCAAAATCCGTTCAACcccAAACAAA          
MafAmut7R TTTGTTTgggGTTGAACGGATTTTGAGT        
MafAmut8F ACTCAAAATCCGTTCAACATCcccCAAA          
MafAmut8R TTTGgggGATGTTGAACGGATTTTGAGT        
MafAmut9F ACTCAAAATCCGTTCAACATCAAAcccA          
MafAmut9R TgggTTTGATGTTGAACGGATTTTGAGT        
NadA2mut1F cccATACTTTAATATGTAAACA             
NadA2mut1R TGTTTACATATTAAAGTATggg     
NadA2mut2F TATcccCTTTAATATGTAAACA             
NadA2mut2R TGTTTACATATTAAAGgggATA     
NadA2mut3F TATATAcccTAATATGTAAACA             
NadA2mut3R TGTTTACATATTAgggTATATA     
NadA2mut4F TATATACTTcccTATGTAAACA             
NadA2mut4R TGTTTACATAgggAAGTATATA     
NadA2mut5F TATATACTTTAAcccGTAAACA             
NadA2mut5R TGTTTACgggTTAAAGTATATA     
NadA2mut6F TATATACTTTAATATcccAACA             
NadA2mut6R TGTTgggATATTAAAGTATATA     
NadA2mut7F TATATACTTTAATATGTAcccA             
NadA2mut7R TgggTACATATTAAAGTATATA     
 
1 Capital letters indicate N. meningitidis derived sequences, small letters indicate sequences added for 
cloning purpose, underlined letters indicate the site included in the oligonucleotide.  
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